EPIGENETIC MODIFICATIONS ABOLISH THE EXPRESSION OF  THE LONG PENTRAXIN PTX3 IN HUMAN TUMORS. by M. Rubino
 1 
UNIVERSITA’ DEGLI STUDI DI MILANO 
Facoltà di Medicina e Chirurgia 
Dipartimento di Biotecnologie Mediche e Medicina Traslazionale 
 
 
 
 
 
CORSO DI DOTTORATO DI RICERCA IN 
PATOLOGIA E NEUROPATOLOGIA SPERIMENTALI 
CICLO XXVII MED/04 
 
 
 
Epigenetic modifications abolish the expression of the long 
pentraxin PTX3 in human tumors 
 
 
 
                                                                                              Dottorando: Marcello Rubino 
                                                                                                         Matricola: R09506 
Relatore: prof. Massimo Locati 
Tutore: Dr.ssa Cecilia GARLANDA 
 
A.A. 2013-2014 
 
 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3 
Table of contents 
Table of content                                                                                                                   3 
Summary                                                                                                                               6 
Introduction                                                                                                  8                    
1. Epigenetic regulation  
   1.1 Epigenetic mechanisms 9 
         1.1.1 Chromatin and nucleosome positioning   9 
    1.1.2 Effect of DNA methylation locus dependent: CpG island  12 
    1.1.3 Histone modifications                             14 
         1.1.4 microRNAs  18 
      1.2 Enhancer and gene regulation 21 
      1.3 Epigenetics in inflammation-associated diseases.   25 
    1.4 The Epigenomics of Cancer  26 
        1.4.1 DNA methylation in Cancer   28 
 
  2. Cancer and Inflammation                                                         30 
      2.1 Cancer Related inflammation: extrinsic and intrinsic pathway     34 
      2.2  Cancer Related inflammation:  players and mechanisms 34  
      2.3 Cancer-related inflammation and adaptive immunity 37 
      2.4 Cancer-inhibitory inflammation 38 
  
3. The pentraxin superfamily 39 
3.1 The Long Pentraxin PTX3  41 
        3.1.1 PTX3 gene, protein structure and regulation 41 
3.2 PTX3 and complement 43  
3.3 PTX3 in host defence  44 
 4 
3.4 PTX3 and polymorphisms 46 
3.5 PTX3 and inflammation 46 
3.6 PTX3 and cancer 48 
          Aim of thesis  50 
   Material and methods 51 
Prediction of regulatory cis-regulatory regions 51 
Analysis of the conserved regions among the species 51 
Cell purification, culture and transfection 51  
Real time RT-PCR (RT-qPCR) analysis 53  
ELISA assay 53 
Chromatin immunoprecipitation  54 
Construct generation and luciferase reporter assay 56 
Generation of PTX3-inflammatory molecular network 57 
Immunoprecipitation of Ago2-bound RNA species (RIP) 58 
PTX3 expression profiles in cancer 58 
Tissue samples 58 
Methylated CpG island recovery assay (MIRA) 59 
Statistical analysis 60 
Immunoistochemistry                                                                                                                            60 
Results                                                                                                                                                   62 
1. Characterization of PTX3 regulatory elements in basal conditions and in response 
 to inflammatory stimuli                                                                                                                     62              62 
1.1 Bioinformatics analysis revealed 2 enhancers that might regulate the long pentraxin 
PTX3                                                                                                                                                   62            62 
1.2 PTX3 enhancers are activated by inflammatory stimuli in the 8387 cell line                         64 
 
 5 
 1.3 PTX3 promoter is active both in basal and in inflammatory condition in the 8387  
cell line                                                                                                                                                  67   
 1.4 Inflammatory cytokines enhance PTX3 expression improving RNA Polymerase II  
activity in a NF-kB dependent manner.                                                                                            69                                                                  
2. PTX3 is directly and indirectly modulated by different miRNAs during inflammatory 
conditions.                                                                                                                                            73 
3. PTX3 regulatory mechanisms in cancer                                                                                       80 
3.1 PTX3 expression in cancer                                                                                                           80 
3.2 PTX3 is silenced in colorectal cancer cells through DNA methylation                                    81 
3.3 PTX3 regulatory regions became active in CRC cells upon co-treatment with 5’aza-dC 
and TNFα.                                                                                                                                            85 
3.4 PTX3 is hypermetilated in several human tumours.                                                                 92 
3.5 PTX3 methylation levels inversely correlate with PTX3 production in tumour 
 samples                                                                                                                                                94 
Discussion                                                                                                                                             95 
- PTX3 expression is regulated by two enhancers during acute inflammation.                            96    
- miRNAs modulate PTX3 activity in inflammatory conditions through direct and indirect 
mechanisms                                                                                                                                         98 
-The methylation of the enhancers silence PTX3 gene in human cancer.                                   100 
References                                                                                                                                          103 
 
 
 
 
 6 
Summary 
PTX3 is a fluid-phase pattern recognition receptor that participates in innate immunity and 
inflammation by modulating complement activation, leukocyte recruitment, extracellular matrix 
deposition and angiogenesis. PTX3 is a biomarker of inflammatory conditions in different 
pathologies in humans, including acute myocardial infarction to autoimmune diseases, infections 
and cancer associated inflammation. Moreover, in vivo studies indicate that PTX3 is involved in 
cancer development, possibly by regulating inflammation. Several tumors lack PTX3 expression, 
such as human esophageal squamous cell carcinoma, where PTX3 is silenced through promoter 
hypermethylation. Taken together, these data suggest that PTX3 is potentially involved in cancer 
development.  
The aim of this study was to identify the regulatory elements involved in the modulation of 
PTX3 expression and gain insight into their mechanisms of action in basal condition, 
inflammatory responses and cancer.  
Using in silico analysis of PTX3 gene we identified two putative PTX3 enhancers located 230 
kbp upstream of the promoter and in the second exon of the gene, overlapping a CpG island, 
respectively. We performed ChIP assay for histone modifications and epigenetic complexes for 
the analysis of these genetic elements in human cell lines, before and after treatment with TNFα, 
that induces PTX3 expression. The results show that these regions are enhancers, but in basal 
condition are enriched with repressive markers H3K27me3 and polycomb group subunities 
(SUZ12 and EZH2). After TNFα treatment, the two enhancers became active gaining H3K27ac 
and the RNA Polymerase II and the first enhancer also acquired the binding for NF-kB.   
We also analysed the effect of the microRNAs, which were predicted to directly target PTX3, 
using bioinformatics analysis. miR-9, miR-29 family and miR-181 family were shown to directly 
target the PTX3 3’-UTR and to significantly reduce both PTX3 mRNA expression and protein 
production. Luciferase assay with PTX3 promoter and with a reporter vector for NF-kb showed 
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that these miRNAs are also involved in signalling pathways controlling PTX3 transcription. 
Moreover, RNA Immuno Precipitation assay demonstrated that miR-9, miR-29 family and miR-
181 family members and PTX3 mRNA were enriched in the RISC complex of macrophages 
after  6h of stimulation with lipopolysaccharide. Moreover, inflammatory miRNAs, such as miR-
146a, miR-155 and miR-132 regulate PTX3 messenger and protein expression, as well, targeting 
the network upstream of PTX3 expression. This suggests that PTX3 gene is strictly regulated by 
several miRNAs acting at different points during inflammatory response. 
Bioinformatics analysis showed that PTX3 is not express in several cancer, including colorectal 
cancer (CRC). ELISA and gene expression analysis in CRC cells confirmed bioinformatics data 
and the treatment with the demethylating agent 5'aza-dC restored PTX3 expression and 
production. ChIP assay for histone modifications and transcription factors in CRC cells showed 
that PTX3 enhancers were inactive and they became active after treatment with 5’aza-dC and in 
response to inflammatory stimuli, thus acquiring the RNA polymerase II and NF-kB.  
Finally, by Methylated-CpG Island Recovery Assay we analysed the methylation of both 
promoter and enhancers of PTX3 in different CRC cells and in 40 CRC patients of different 
tumor stages. Data demonstrated that PTX3 regulatory regions were significantly methylated in 
all the cell lines and in all tumour stages, compared to their healthy counterparts. Moreover, the 
methylation started from the adenoma. Taken together, these data show that PTX3 methylation is 
involved in the inhibition of the PTX3 expression in CRC and suggest that PTX3 may have a 
protective role in the pathogenesis of this tumour. 
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Introduction 
 
1. Epigenetic regulation 
 
In eukaryotic cells, gene regulation is controlled for the whole cell cycle life, by a complex 
molecular network of interactions made by several players, like transcription factors, RNA 
polymerases, regulatory sequences, and co-regulator proteins. Epigenetics is an essential 
regulator of this interplay. The term epigenetics was introduced for the first time in the 
nineteenth century by Conrad Waddington, who defined it as ‘‘the branch of biology which 
studies the causal interactions between genes and their products which bring the phenotype into 
being.’’[1]. Today the current definition of epigenetics is the set of mechanisms that regulates 
gene expression without entailing modifications to the DNA sequence, but that are  meiotically 
and/or mitotically heritable [2, 3, 4]. In this great and complicate network, the final effects are 
the sum of the interactions of each single modification that can lead a positive or a negative 
regulation. Gene expression is epigenetically regulated through the modulation of chromatin 
structure and DNA and RNA-based biological processes, like the binding of transcription 
factors to regulatory regions, such as promoters and transcription elongation. Epigenetic 
modifications are fundamental for the mobility of transposable element, DNA-protein 
interactions, gene and microRNA expression, cellular differentiation, embryogenesis, 
inactivation of chromosome X and genomic imprinting [5].  Each single cell has the own 
epigenetic mark, which characterizes the state, age and type of cell. Alterations of epigenetic 
mechanisms, like a modification added in a wrong place or in a wrong time, induce the 
development of many diseases [6]. This is a further evidence of the major role of epigenetics in 
maintaining normal development. Many epigenetic marks, like DNA methylation and 
microRNAs silencing, are highly adaptable, in order to respond to both external and internal 
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factors. Epigenetics, which allows the interaction between genome and external environment, is 
involved in pathogenesis of diseases. Indeed, various disease-associated nutritional, chemical, 
physical and psychosocial factors have been correlated with changes to the epigenome, 
particularly DNA methylation [7]. Furthermore epigenomic variations can regulate both 
deterministic and stochastic choice of allelic expression, which correlate to complex pathologies 
in human populations. 
 
1.1 Epigenetic mechanisms 
 
Epigenetic mechanisms work together creating a complex network of interactions,  an 
‘‘epigenetic landscape’’, for the control of gene expression at both transcriptional and 
translational levels.  
Based on the type of action, it is possible to distinguish four main groups of epigenetics 
modifications:  nucleosome positioning, covalent histone modifications, DNA methylation and  
miRNAs regulation.  
 
1.1.1 Chromatin and nucleosome positioning   
 
Chromatin is a complex of macromolecules consisting of DNA packaged by histone proteins. 
This structure allows to DNA to be compacted in the cell, prevents DNA damage, reinforces the 
DNA macromolecule during mitosis and regulates gene expression and DNA replication. 
Chromatin is organized in three levels. The principal unit of chromatin is nucleosome, which is 
made by 146 base pairs of DNA rolled up around an octamer of histone proteins, composed by 
a tetramer of  2 histone 2B (H2B) and 2 histone 2A (H2A) molecules, flanked by dimers of H3 
and H4 histones [8]. This first level of organization is know as euchromatin. Nucleosomes are 
bound by histone linkers (H1 or H5) with consequent further compaction into 30 nm fibres, 
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which represent the second level of chromatin organization, the heterochromatin. Finally, 
during mitosis and meiosis the 30 nm fibers are further packed (Figure 1).  
The location of nucleosome histone octamer, the nucleosome positioning, depends on the 
curvature and rigidity of the DNA sequence. This location is a key mechanism for several 
biological processes, like gene transcription. The presence of the nucleosome acts like a 
transcriptional repressor, impeding the binding of proteins, as polimerase II and transcription 
factors, to DNA. Indeed a transcriptionally active gene is characterized by a nucleosome-
depleted region (NDR) directly upstream of the promoter transcription start site (TSS). On the 
contrary, the nucleosome covers the TSS of transcriptionally inactive genes, impeding the 
binding of transcription activators [8]. Nucleosome occupancy is regulated by ATP-dependent 
chromatin remodeling enzymes [9, 10], which are multi-protein complexes that alter the 
nucleosome structure through the use of the energy derived from ATP hydrolysis. ATP 
dependent chromatin remodelers are classified in base of their mechanism of action. Some 
complexes bind nucleosomes and adjacent DNA linker and hydrolyze ATP to slide 
nucleosomes in the direction of the linker, while others can twist nucleosomes or create a loop 
with another DNA region (Figure 2). These remodelers can both activate and repress gene 
expression by modifying nucleosome occupancy pattern [11, 12]. In-vitro experiments showed 
that these enzymes maintain an equal spacing between nucleosomes, organize the nucleosome 
structure and also an higher-order chromatin structures. Moreover some remodelers are 
involved in the crucial steps of cell growth and division, like in DNA double-strand break repair, 
regulate transcriptional repression, progression of cell cycle and are important for the 
maintenance of embryonic stem cells pluripotency [13]. Mutations or alterations of this enzyme 
activity are found in some type of cancers, favoring self-sufficiency in cell growth [14].  
 11 
 
Figure  and legend are from: Cizhong Jiang
 
& B. Franklin Pugh Nucleosome positioning and gene regulation: 
advances through genomics,  Nature Reviews Genetics ,2009 
Figure 1: Structure of a nucleosome core.  
Histones are shown in light grey, and the DNA helix is shown in dark grey with a pink backbone. Basic amino 
acids (lysine and arginine) within 7 Å of the DNA are shown in blue to emphasize the electrostatic contacts 
between the DNA phosphates and the histones. b | A schematic of DNA wrapped around a nucleosome. Examples 
of histone tail modifications (Ac, acetylation; Me, methylation) and histone variants (H2A.Z and H3.3) are shown. 
Arrows indicate the replacement of canonical histones with histone variants 
 
 
 
Figure and legend are from: Cizhong Jiang & B. Franklin Pugh , Nucleosome positioning and gene regulation: 
advances through genomics., Nature Reviews Genetics ,2009 
Figure 2 Nucleosome state. 
a | A stable nucleosome. b | A remodelled nucleosome. c | An evicted nucleosome. Three transcription factor 
binding sites are shown in red, green and blue, respectively. The red and blue sites become accessible only during 
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remodelling, either by nucleosome sliding, as indicated by the arrows in a, or by chromatin remodelling complexes 
(for example, ISW2, SWR1 and SWI/SNF) that 'extract' DNA from the nucleosome surface, as shown in b. Owing 
to rotational phasing, the green site is always accessible in the various states. Nucleosome eviction (c) might be 
necessary to assemble a pre-initiation complex and to transcribe the underlying DNA. Anti-silencing function 1 
(Asf1) and H2A.Z-specific chaperone (Chz1) are examples of histone chaperones. Ac, acetylation 
 
1.1.2 Effect of locus-dependent DNA methylation: CpG island  
 
The DNA methylation is the covalent addition of a methyl group onto carbon 5 of the cytosine 
residue (5mC) of a CpG dinucleotide, catalyzed by DNA methyltransferas (DNMTs) enzymes 
[15]. More than half of all genes have regions with high concentration of these CpG 
dinucleotides, called “CpG islands” (CGIs) [16]. These CGIs are at least 200 base pair long, and 
are localized in the 5' promoter region of 50% genes. In a normal differentiated cell, there is a 
global hypermethylation of CpG islands, whereas promoter CG Islands of active genes are 
hypomethylated [16]. Genome-wide studies of the methylome with modern techniques like 
bisulfite-sequencing, have demonstrated that the position of the methylation influences genes 
control in different ways. For example, methylation near TSS blocks gene expression, but 
methylation in the gene body stimulates transcription elongation, and it may regulate splicing. 
Other important regions are the so called “CpG island shores”, located up to 2 kb upstream of 
some promoter CGIs. As for the TSS, also the methylation of these regions correlates with gene 
expression (Figure 3). DNA methylation represses gene expression through direct interference 
with the binding of specific transcription factors and with the binding of complexes that can 
positively remodel the chromatin and through the direct binding of methyl-binding domain 
proteins (MBDs) [15]. These MBDs, act together with the other repressor complexes such as 
histone methyltransferases and histone deacetylases, in order to obtain chromatin 
reconfiguration and gene silencing [17].  CGIs DNA methylation plays a fundamental role in 
the repression of a set of genes germ cell-specific, genomic imprinting [18] X chromosome 
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inactivation [19] and regulation of tissue aging [20]. The methylation in regions with repetitive 
elements such as centromeres and transposable elements, like LINE, regulates chromosomal 
stability [21] and genome stability, too. DNA methylation is finely regulated by mechanisms for 
add , maintain and remove methyl group. The methyltransferases enzymes DNMT3A and 
DNMT3B promote de novo DNA methylation in early development [22]. DNMT1 instead is 
the “methyltransferase maintainer”, given that it alone maintains the DNA methylation pattern 
[19]. DNMT1 preferentially methylates only 1 of the 2 DNA strands and is used to maintain 
firmly the degree of DNA methylation through cell division [22]. All the three DNMTs are 
necessary for both embryonic and neonatal development. Methylation activity is essential for 
viability of somatic [23] or cancer cells [24].  
DNA methylation is a plastic event and can be actively or passively regulated also by 
demethylating agents, such as activation-induced cytidine deaminase (AID), thymine DNA 
glycosylase (TDG) and the ten-eleven translocations (TET) methylcytosine. 
An altered activity of these enzymes can lead to alteration of gene’s activation [25,26,27] or 
genomic instability events underlying the human carcinogenesis [28]. 
             
Figure and  legend are From: Miller JL, Grant PA., The role of DNA methylation and histone modifications in 
transcriptional regulation in humans, Subcell Biochem. 2013 
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Figure3: Effects of DNA methylation throughout the genome. 
DNA methylation is found at inter- and intragenic regions throughout the genome. DNA methylation dependent 
transcriptional activity is contingent on CpG dinucleotide genic location and density. Normal methylation events 
and subsequent effects are shown on the left. ( a ) CpG islands at promoters are normally unmethylated resulting in 
gene expression. However, aberrant hypermethylation at the same promoter results in corepressor complex 
recruitment and subsequent gene repression. ( b ) Intragenic regions characterized by scattered CpG dinucleotides 
located 2 kb upstream of the promoter called CpG island shores are regulated in the same manner as ( a ). ( c ) DNA 
methylation within the gene body prevents initiation of transcription from spurious sites in the gene. If unmethylated, 
these sites become transcriptional start sites resulting in an incorrect product        
 
1.1.3 Histone Modifications 
 
Histones are small proteins, with a molecular weight of 11_20 kDa, constituted by a globular 
domain and charged tails which have numerous lysine and arginine residues. Histones regulate 
the chromatin dynamics either by altering the structure, through changing the electrostatic 
charge and influencing nucleosome positioning, or providing sites for the recognition of 
proteins involved in chromatin remodelling through specific modifications. [29,30].  Histone 
modifications consist in numerous covalent reactions involving the histone N-terminal tails, and 
form the code (known as histone code) that regulates DNA wrapping around the histone 
proteins themselves. Histone tail modifications include methylation, acetylation, ubiquitination, 
sumoylation, phosphorylation and ADP ribosylation [31] of specific amino acids. The most 
studied modifications are methylation and acetylation of specific lysine residues on histones H3 
and H4. In these N-terminal tails, the adding of an acetyl group compensates the positive charge 
of the lysine residues, reducing the tight bond between DNA and histones and opening the 
chromatin configuration enough to be accessible and leading to gene transcription [32]. These 
histone modifications are regulated by the cross-talk between histone acetyltransferases (HATs) 
and deacetylases (HDACs), which, respectively, introduce and remove an acetyl group.  
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According to cellular location and function, HATs can be divided into 2 distinct groups: the 
nuclear A-type HATs and the cytoplasmic B-type HATs [33]. The firsts affect gene 
transcription, whereas the cytoplasmic HATs type acetylates nonhistone proteins. Based on the 
similarities of the sequence, HATs can be classified into three categories: the MYST families, 
p300/CBP and Gcn5/ PCAF. These families generate a network of interplay and through the 
acetylation of target promoter regions and general acetylation, have an important role in 
differentiation, development and cell cycle progression [34]. In addition to these chromatin 
modifying enzymes, there are chromatin binding proteins, called epigenetic ‘‘readers’’, like the 
bromodomain proteins which can read lysine acetylation marks. They are involved in the 
regulation of several cellular processes including signal transduction, cell cycle regulation, 
apoptosis, and cell growth [35]. HDACs can be either cytoplasmic or nuclear and can 
deacetylate both non nonhistone and histone proteins. Cytoplasmic deacetylation leads to post-
translational modifications of chaperone proteins and transcription factors. Furthermore, it can 
affect several important pathways, such as nuclear factor kappa B (NF-kB)  and the  gene of 
phosphatase and tensin homolog (PTEN)- dependent pathways [36,37]. The catalytic activity of 
HDACs involves the association with other complexes, such as the sirtuins, very important for 
the maintenance of the stemness [38].  
Histone methylation is a dynamic modification, regulated by two classes of enzymes: histone 
methyltransferases (HMTs) and histone demethylases (HDMTs), which, introduce and remove 
methyl groups, respectively. These enzymes can promote or repress genes, depending on the 
specific substrate (figure 4). The arginine and lysine methylation on both histones or nonhistone 
regulatory regions or proteins such as TFs, modulates chromatin structure and also gene 
expression [39]. For example, methylation of histone H3 lysines 4 and 36 is associated with 
active genes expression, (with transcription activity and elongation, respectively), whereas 
methylation of histone H3 lysines 9 and 27 correlates with gene silencing. 
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Histone methyltransferases and demethylases are often part of a larger protein complexes 
regulating gene transcription. For example, the H3K27me3 is associated to the activity of the 
chromatin repressor complex Polycomb. Polycomb group (PcG) controls the accessibility of 
regulatory elements on the transcription machinery, through repression of proteins [29].   
Finally, histones can be targeted by posttranslational modifications such as ubiquitination, 
ADP-ribosylation and phosphorylation, which also play an important role in gene regulation. 
For example, the phosphorylation of serine 10 is inversely correlated with lysine methylation 
[40]. Histone modifications works together with chromatin remodelers and DNA methylation 
creating an "epigenetic code" which characterized and defines genomic regions based on their 
activity status. Regions transcriptionally inactive have histones methylated and deacetylated on 
Lys 9 and 27 and high levels of methylated DNA, whereas genomic regions transcriptionally 
active are hypomethylated at level of DNA and have a chromatin structure globally acetylated 
and specifically methylated on Lys 4 and Lys 36. The alteration of histone modifiers activity 
caused by mutations may affect the whole epigenetic regulation mechanisms resulting in 
aberrant gene expression patterns. 
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Figure and legend are from:  Xiang Zhang and Shuk-Mei Ho, Epigenetics meets endocrinology, J Mol Endocrinol 
February 1, 2011 
Figure 4: Histone modifications regulating gene activation. 
DNA methylation and histone modification are two major epigenetic mechanisms that corroborate in regulating 
endocrine-related gene expression. Packaging genes into active or inactive chromatin determines whether they are 
transcriptionally accessible or not. The N-termini of histones have specific amino acids that are sensitive to 
posttranslational modifications, which contribute to chromatin status. Moreover, hypermethylation of promoter is 
associated with transcriptional silencing due, in part, to the loss of affinity for transcriptional factors such as the 
nuclear receptor (NR) and accessibility by the transcriptional machinery as represented by RNA Pol II complexes. 
The inactive chromatin has increased affinity for methylated DNA-binding proteins (MBPs), which further recruit 
histone deacetylases (HDACs), DNA methyltransferases (DNMTs), and histone methyltransferases (HMTs), and 
other corepressors. Methylated promoters are associated with unique repressive histone markers, which classically 
include trimethylation of histone 3 (H3), lysine (K) 9, and H3-K27. In contrast, unmethylated promoters are 
associated with gene transcription. They have increased affinity for histone acetylases (HATs), histone 
demethylases (HDMs), DNA demethylases (DMEs; e.g. DNA N-glycosylase), and histone marks associated with 
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active chromatin, including acetylated H3-K9 and trimethylated H3-K4. Nucleosome remodeling such as 
repositioning and ejection in promoter results in gene transcription (bent arrow). Me, histone methylation; Ac, 
histone acetylation; black filled circle, methylated CpG dinucleotides; white filled circle, unmethylated CpG 
dinucleotides; filled purple circle, hormone or endocrine disruptors that bind to NR. 
 
1.1.4 microRNAs  
 
miRNAs are short ( about 19-25 nucleotides (nt) in length) non-coding RNAs (ncRNAs) that  by 
binding to specific mRNA targets, modulate their expression, through degradation and/or 
translational inhibition [41] .  Thus, microRNAs are the only epigenetic mechanisms that regulate 
gene expression at the post-transcriptional level. miRNA genes are often located in fragile 
regions and deleted sites in human genome, in introns and rarely in exons and can be organized 
in monocistronic or polycistronic units [42,43]. One miRNA alone may regulate hundreds 
mRNAs, thus modulating gene expression networks and also whole pathways. Indeed miRNAs 
are involved in many contexts such as development and maintenance of tissue differentiation 
[44], inflammatory response [45, 46], autoimmune diseases (47) and also in cancer [48]. 
miRNA genes are transcribed by RNA polymerase II and processed into mature miRNAs 
through the canonical miRNA biogenesis pathways (figure 5). The RNA polymerase II 
generates a long hairpin double strand RNA (pri-miRNA) that is cleaved by endonuclease 
Drosha, a member of RNAse III family, generating a precursor miRNA (pre-miRNA) 70 nt-
long. There is also a non canonical biogenesis, in which the pre-miRNA is generated through 
mRNA splicing machinery, avoiding the endonuclease digestion. The pre-miRNAs is exported 
in the cytoplasm by the nuclear export protein exportin 5 and here is further processed by 
another RNase III enzyme, Dicer, to a double strand miRNA 22 nt-long. This mature miRNA is 
loaded into the RNA-induced silencing complex (RISC), a functional ribonucleoprotein 
complex which mediates the post-transcriptional gene silencing of the miRNAs (figure 5). 
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RISC is composed by multiple protein factors, like Argonaute proteins, which are the key 
catalytic enzymes of the complex. Argonaute proteins, like Ago II, bind miRNAs and are 
essential for the regulation of their target mRNAs. The binding of the miR-RISC complex to 
3’UTR of target mRNA is regulated by the "seed region", a sequence of 2–8 nucleotides, 
located at the 5ʹ end of the mature miRNA. miRNAs may silence gene through mRNA 
destabilization and decay, accelerating uncapping and deadenylation and/or translational 
repression, inhibiting translation initiation, or translation post-initiation [49-52]. In the 
deadenylation process the polyA tail is removed from the mRNA, through the activity of 
deadenylases, which induces mRNA instability and cleavage. The inhibition of the initiation 
factor 4E (EIF4E) leads to block of mRNA translation. In mammalian, mRNA destabilization is 
the dominant way of inhibition operated by miRNAs. This occurs possibly with the 
involvement of P body proteins, which are cytoplasmic processing bodies enriched with 
proteins and enzymes that sequester the messenger from the translational machinery and 
degrade it. 
Recent studies demonstrated that several miRNAs, more than 100, are produced by cells of the 
immune system and that they can modulate, through the molecular pathways, the function and 
development of innate and adaptive immune responses. 
Thus, in the last years some pharmaceutical companies have tried to use miRNAs for 
therapeutic treatment. 
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Figure and legend are from Roberto Papait,Carolina Greco, Paolo Kunderfranco, Michael V. G. Latronico, 
Gianluigi Condorelli, Epigenetics: a new mechanism of regulation of heart failure? Basic Res Cardiol 2013. 
Figure 5: Biogenesis of microRNAs 
Transcription of primary micro RNA (Pri-miRNA) from miRNA genes is followed by cleavage to 
precursor mRNA (Pre-miRNA) by the Drosha nuclear RNase III. The Pre-miRNA is then exported to the 
cytoplasm by exportin via nuclear pore. In the cytoplasm, Pre-miRNA is further processed by RNase 
activity of Dicer to the mature micro RNA duplex. The duplex loads onto Argonaut ribonucleases in the 
RISC complex and separates. One of the mature miRNA strands (red strand) mediates small interfering 
RNA silencing by degrading the target mRNA or interfering with translation. The outcome of RISC 
formation varies with the degree of complementarity of the seed sequence of miRNA and 3' u ntranslated 
regions (UTR) of the target mRNA. 
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       1.2 Enhancers and gene regulation  
 
Enhancers are short DNA cis-regulatory elements that enhance the transcription of target gene 
promoters influencing the destiny of cells during development and differentiation [53]. Enhancer 
sequences are characterized by short different DNA motifs containing binding sites for specific 
transcription factors. These motifs confer to enhancers their specificity of action: an enhancer 
binds different co-activators and co-repressors molecules, in a manner tissue and stimuli 
dependent, and their combined effect determine the intensity of enhancer effect. A functional 
characteristic of enhancers is that they act independently by the orientation and distance to their 
target genes: they may remodel chromatin to form a loop on the gene target, also located at 
distances of several megabases [54].  
The physical interaction between specific enhancers and target promoters can be investigated 
through the chromosome conformation capture (3C) technique [55, 56]. This loop is the result 
of interplay between negatively regulatory elements (insulators) and activators, which interact 
with the RNA polymerase II (Pol II) and with transcriptional coactivator complexes, like p300, 
to bind enhancer loops together with the transcription apparatus [57]. Indeed, enhancers 
modulate components of the basal transcription machinery [58, 59, 60] and can regulate Pol II 
activity at transcript initiation, elongation, or termination. The first step of transcription is the 
bind of RNA Pol II and cofactors to gene promoters, forming the Transcription preinitiation 
complex (PIC), after which there is the elongation phase and the Polymerase II complex moves 
across gene body, transcribing the gene (figure 6). 
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Figure and legend are from Epigenetics: Barrero MJ, Malik S. The RNA Polymerase II Transcriptional Machinery 
and Its Epigenetic Context, book Epigenetics: Development and Disease 2012 
Figure 6 :Transcription by Pol II is a multi-step process . The figure depicts a simplified transcription activation 
pathway that commences when transcriptional activators bind to their cognate sites in the regulatory region of the 
gene that may be buried in chromatin. These factors recruit a series of chromatin coactivators that can both 
covalently modify nucleosomes at specific histone residues and mobilize the nucleosomes via ATP-requiring 
reactions. The resulting intermediate (I) contains chromatin that is characterized by distinct covalent modifications 
such as acetylation (Ac) and methylation (Me); some nucleosomes may be “evicted”. The activators then recruit 
Mediator (intermediate II). Although the intact Mediator consisting of the core and the kinase module might be 
recruited with subsequent loss of the kinase module as the PIC matures, only the core Mediator is shown. PIC 
assembly entails entry of the various GTFs and Pol II. After transcription initiation, Pol II clears the promoter. Prior 
to fully entering  the elongation phase , Pol II, which by now is phosphorylated at Ser5, may pass through a capping 
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checkpoint. The scaffold complex (intermediate III) containing a subset of GTFs and Mediator remains behind at the 
promoter and can contribute to subsequent rounds of transcription. At the capping checkpoint, Pol II becomes 
associated with elongation factors including DSIF and NELF. The capping enzyme (hCE) modifies (7MeG) the 
nascent RNA. Pol II is released from this pause through recruitment of P-TEFb. 
 
This elongation can be inhibited by blocking Pol II. Enhancers promote transcription both by 
favouring PIC formation on the promoter and also by releasing paused Pol II, activating specific 
complexes and allowing elongation [61]. Moreover, recent studies showed that RNA Pol II 
binds not only TSS of promoter regions but also enhancers, resulting in the generation of a 
transcript, called eRNA [62]. This eRNA can modify chromatin structure on target promoter, 
increasing target gene expression. An active enhancer is nucleosomes free, thus the DNA is 
accessible to transcription factors. Furthermore, the different state of enhancer activation can be 
detected by specific histone modification marks located on the nucleosomes in proximity of the 
enhancer (figure 7). An active enhancer is characterized by the present of histone H3 lysine 4 
monomethylation (H3K4me1) and the open chromatin mark H3K27 acetylation (H3K27ac). An 
intermediate phase of activation is characterized by the presence of a “bivalent domain”: the 
nucleosomes show both H3K4me1 and one of the closed chromatin mark histone H3 lysine 
9/27 threemethylation (H3K9me3 or H3K27me3). This kind of enhancer is called "poised" and 
its activity is reduced by the effects of chromatin repressor complexes like Polycomb and is 
recognised by the presence of H3K27me3 and H3K9me3. These genes are usually found in 
stem cells, whereas during differentiation, they can become fully activated (loosing 
H3K9/27me3) or repressed (loosing H3K4me1) [63–65]. 
In contrast, an inactive enhancer localizes with nucleosomes and thus, does not have 
transcription factors.  
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Figure and legend are from:  Daria Shlyueva, Gerald Stampfel and Alexander Stark,  Transcriptional enhancers: 
from properties to genome-wide predictions, Nature 2014. 
Figure 7: Chromatin accessibility and histone marks at regulatory elements. 
a) Chromatin is shown as a ‘gatekeeper’ for transcription factor (TF) binding and enhancer activity. Densely 
positioned nucleosomes can restrict access for transcription factors (both activators and repressors), RNA 
polymerase II (Pol II) and other proteins. Accessible (that is, nucleosome-free) regions can be bound by these 
proteins, which define and mediate the identity of a region. The transition from ‘open’ to ‘closed’ chromatin, and 
vice versa, is determined by regulatory proteins, including pioneer transcription factors. Insulator proteins and other 
architectural proteins also bind to open regions, and they make up a substantial proportion of sites that are accessible 
across multiple cell types. b)  Histones that flank active enhancers are often marked by histone H3 acetylated at 
lysine 27 (H3K27ac) and H3 monomethylated at lysine 4 (H3K4me1. c) Some closed or poised enhancer regions 
can bear the active H3K4me1 and the repressive Polycomb protein-associated H3K27me3 marks. d) Latent 
enhancers are located in closed chromatin and are not pre-marked by known histone modifications. However, in the 
presence of external stimuli the DNA becomes accessible, and flanking nucleosomes acquire H3K4me1 and 
H3K27ac marks. 
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1.3 Epigenetics in inflammation-associated diseases 
 
In the last ten years several studies showed the involvement of aberrant epigenetic 
modifications in the aetiology of inflammatory and autoimmune diseases. There is a strong 
interplay between epigenetic and inflammation. Different studies have demonstrated that 
inflammation can modify epigenetic machineries, enhancing the whole genome DNA 
methylation [66]. The inflammation induces the epigenetic reprogramming that leads to 
aberrant immune responses. For example, the activity of the NF-kB transcription factor, 
important for the regulation of immune responses, including the differentiation of B and T cells, 
haematopoiesis and acute inflammatory responses, is associated to alterations of the  activity of 
epigenetic regulators, like DNA Methyltransferases and Histone Methyltransferases and 
Polycomb group [67-70]. Moreover, epigenetic mechanisms themselves, can modulate the 
inflammatory response and thus, the inflammation-induced transcription. In general, the 
epigenetic control of transcription factors and key cytokines regulating the cells of the innate 
and adaptive immune systems is important in the differentiation, development, function and 
phenotype of DCs, neutrophils, monocyte/macrophages, and Th cells. For example, in Th cell 
differentiations, epigenetic mechanisms like histone modifications associated with silent 
heterochromatin and active euchromatin (H3K9me3 and H3K4me3 respectively), affect the 
production and release of IFN-γ and IL-4. Aberrations of these epigenetic modifications are 
associated with various diseases, such as rheumatoid arthritis, multiple sclerosis, type 1 diabetes, 
inflammatory bowel disease, systemic lupus erythematosus, and asthma.  
The epigenetic machinery is a plastic mechanism that changes in a specific manner in response 
to environmental factors. These epigenetic variations can modify or influence different 
pathways, including the immunity responses and also lead to alterations of gene regulation 
mechanisms. Thus explain the complexity of human diseases (Figure 8).   
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Figure and legend are from: Harakd Renz et al., Gene-environment interactions in chronic inflammatory disease, 
Nature Immunology 2011  
Figure 8: A new paradigm for the development of chronic inflammation. 
The traditional simplistic paradigm of chronic inflammatory disease development has been revised to a more 
complex understanding of the cornerstones of these conditions. Epigenetics (blue) represents a key mechanism 
linking genetic components (yellow) and the environment. Disease development depends on intimate interaction 
between intrinsic mechanisms (red) and extrinsic mechanisms (green) in a temporal and spatial way. 
 
1.4 The Epigenomics of Cancer  
 
Epigenetic dysregulation correlates with all the processes generating cancer. Indeed, together 
with mutations, also stochastic epigenetic variations increase the susceptibility to cancer. 
Alteration of epigenetic mechanisms can be caused by mutations in the genes that encode for 
these mechanisms or by epigenetic modifications in such genes, generating a positive feedback. 
Indeed epigenetic changes can occasionally result from single nucleotide polymorphisms in 
proximity to promoter regions. Feinberg’s group hypothesized that the dysregulated epigenetic 
mechanisms work together with mutations of the crucial genes which alter pathways that 
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leading to cancer development [71] (Figure 9). Moreover, the epigenetic changes themselves 
contribute to increase mutation frequency. The mutations in genes controlling epigenetic were 
found in rare solid tumours, and in haematopoietic malignancies.  Cancer cells show some 
global epigenetic aberrations, like DNA hypomethylation, histone deacetylation and 
hypomethylation, down-regulation of miRNAs.  More in details, focusing on histone 
modifications in cancer, a general loss of histone H3 lysine 4 trimethylation (H3K4Me3) and 
lysine 9 acetylation (H3K9Ac) was shown. Furthermore, the gain of histone H3 lysine 27 
trimethylation (H3K27me3) and lysine 9 trimethylation (H3K9me3) at specific tumor 
soppressor gene promoters silenced them, contributing to tumorigenesis [72]. Indeed, 
overexpression of Polycomb group promotes tumor growth both in vitro and in vivo [73], and is 
found in different cancers, such as lymphoma melanoma, breast and prostate cancers [74]. 
Moreover, histone H3 lysine 9 methyltransferase is important for carcinogenic initiation and 
progression [75].  
In cancer there is a global alteration in miRNA expression [76]: most miRNAs are down-
regulated by epigenetic or genetic events, whereas some, depending on the kind of tumor, are 
upregulated. For example, miR-17-92 cluster is overexpressed in chronic myeloid leukemia and 
in breast and lung cancers, favouring tumour development, silencing the transcription factor 
E2F1, which is a major cell cycle regulator. Aberrant DNA methylation is the most studied 
epigenetic modification in cancer. For example, genes bound to Polycomb Repressive Complex 
proteins in embryonal cells, which DNA is methylated in cancer, are of great interest. 
All these alterations provide a growth advantage to neoplastic cells respect to normal cells, 
leading to uninhibited cellular proliferation, apoptotic deficiency and tumorigenicity (Figure 9).  
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 Figured and legend are from: Winston Timp, Andrew P. Feinberg, Cancer as a dysregulated epigenome allowing 
cellular growth advantage at the expense of the host, Nature Reviews Cancer 2013 
Figure 9: Collaboration of epigenetic modification and mutation in the hallmarks of cancer. 
The epigenome sits at the intersection of the environment, genetic mutation and tumour cell growth. Environmental 
factors, such as carcinogens or diet, as well as injury and inflammation, cause epigenetic reprogramming. The 
epigenome also accumulates damage stochastically and through ageing. The machinery for maintaining epigenetic 
integrity can be stably disrupted in either of two ways: by mutation or by epigenetic change itself with positive 
feedback.  
 
1.4.1 DNA methylation in Cancer   
 
Several studies show the key roles of DNA methylation in tumors. Aberrant DNA methylation 
is transmitted among generations comporting a growing increase of epigenetic alterations in the 
daughter cells. Genome-wide DNA methylation studies in colon cancer, versus healthy colon 
samples showed a demethylation in some regions, megabases long, located across multiple 
chromosomes [77-79]. Some of these demethylated domains are associated with proteins in the 
nuclear lamina. DNA demethylation can occur in an active or passive manner [80, 81]. Active 
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DNA demethylation is operated by enzymes that modify methylation through oxidation, 
hydroxylation, or deamination and that are independent from DNA replication [82]. Important 
regulators of demethylation are activation-induced cytidine deaminase (AID) and ten-eleven-
translocation (TET), which induces hydroxylation [83]. In contrast, passive DNA demethylation 
occurs during DNA replication, when the mechanisms responsible to maintain DNA 
methylation are impaired.  
Furthermore, genome of cancer cell is characterized by specific hypermethylated regions 
corresponding to CpG islands of promoter oncosuppressor genes [28, 84, 85, 86]. For example, 
in various cancers DNA hypermethylation occurs in genes controlling DNA repair, such as O6-
methylguanine-DNA methyltransferase (MGMT) and the mismatch-repair gene MLH1, and cell 
cycle, like PTEN [87]. Hypermethylation of MGMT in cancer is associated to higher 
susceptibility to genetic mutations in critical genes such as KRAS and p53 [88]. Moreover, 
aberrant MLH1 promoter methylation induces microsatellite instability, which is a key factor in 
several cancers, like colorectal and endometrial cancers. The human colon cancer methylome 
shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores . 
The alteration of DNA methylome is a consequence of alterations of the epigenetic machineries. 
Indeed, in different tumors, like colorectal cancer, DNMT1 mutations were found (Kanai et al., 
2003), whereas DNMT3A alterations are common in acute myeloid leukemia and in 
myelodysplastic syndromes [89].  
Also genetic mutations in Methyl-binding domain (MBD) proteins, such as MeCP2,  have been 
reported in several cancers. 
Aberrant DNA methylation is also a diagnostic biomarker in biopsy specimens and in body 
fluids such as sputum, serum, saliva, pleural or peritoneal effusions and urine. For example, p16 
methylation is a possible biomarker to assess a patient’s risk to develop lung cancer. Thus the 
study of DNA methylation can be useful to prevent cancer, through the development of drugs 
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able to revert specific DNA methylation. Finally, DNA methylation is also used to assess 
response to chemotherapeutic agents and clinical outcomes [66]. 
 
   2.   Inflammation and cancer 
 
         2.1 Cancer Related inflammation: extrinsic and intrinsic pathways     
 
Connections between cancer and inflammation were found since the nineteenth century, based 
on the observations that an inflammatory infiltrate was present in tumours, and that often 
tumors arise at sites of chronic inflammation.  Epidemiological studies have shown that chronic 
inflammation has many ways to increase the risk of developing cancer [90] (in particular 
cervical, bladder, ovarian, prostate, intestinal, gastric, oesophageal and thyroid cancer). These 
ways include microbial infections (for instance infection with Helicobacter pylori, that  is 
associated with gastric mucosal lymphoma and gastric cancer), autoimmune diseases ( such as 
inflammatory bowel disease that is associated with colon cancer) and various inflammatory 
conditions. Furthermore, the overexpression of inflammatory cytokines or the transfer of 
inflammatory cells promotes the development of tumours in preclinical models.  
The risk of developing certain cancers, like colon cancer, can be reduced by non-steroidal anti-
inflammatory drugs [91-93], that reduce also the mortality associated to these cancers. On the 
same line, the incidence and growth of cancer can decrease through the targeting of 
inflammatory cells, the principal transcription factors involved in inflammation (such as nuclear 
factor-κB , NF-κB and STAT3) and inflammatory mediators ( cytokines and chemokines, such 
as  interleukin 1 beta , IL-1β and tumour necrosis factor-α, TNF-α). 
The hallmarks of Cancer-related inflammation (CRI) are the presence of inflammatory 
mediators (like prostaglandins, chemokines and cytokines) and inflammatory cells in tumour 
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tissues, angiogenesis and tissue remodelling, like those observed in chronic inflammatory 
responses and tissue repair. 
Recent studies have demonstrated that also complement effectors, like C5a, are potent 
proinflammatory mediators involved in CRI and that they can enhance tumors growth [94]. The 
proteins of the complement cascade are abundant in biological fluids of patients with different 
types of tumor [95–97,] and elevated complement levels correlated with lung tumor size [98].   
CRI can be conceptually divided in intrinsic and extrinsic inflammation.  
The intrinsic pathway is regulated by genetic events, like oncogene mutation or overexpression, 
which cause cancer and orchestrate the construction of an inflammatory microenvironment. The 
extrinsic pathway, activated by infectious or inflammatory conditions, can increase cancer risk . 
(figure 10). Classical examples of cancers associated to the extrinsic pathway are mucosa-
associated lymphoid tissue (MALT) lymphoma and gastric cancer, triggered by persistent 
Helicobacter pylori infection or colorectal cancer associated to IBD, or hepatocellular 
carcinoma (HCC) associated 2 infections with hepatitis C (HCV) or  B (HBV) viruses. 
By investigating why inflammatory mediators and cells are present in the microenvironment of 
all tumours independently from epidemiological basis for inflammation, the intrinsic pathway 
was discovered. Various studies demonstrated that an early genetic event that is sufficient and 
necessary for the starting of human tumour development, directly promotes the formation of an 
inflammatory microenvironment [99]. An important mechanism that promotes intrinsic 
inflammation is the response to cellular stresses, in particular DNA damage.  
The most frequently mutated oncogenes in human cancer are the members of the RAS family 
which activate the oncogenic components of the RAS–RAF signalling pathway that, in turn, 
induce the production of inflammatory chemokines and cytokines that promote inflammation 
[100–102].  
Another relevant oncogene is MYC, which encodes for a transcription factor over expressed in 
many human tumours. The deregulated expression of MYC promotes and maintains any key 
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aspects of the tumour phenotype. MYC promotes the cell-autonomous proliferation and also 
induces a reconfiguration of the extracellular microenvironment, with the help of inflammatory 
cells and mediators. The transcriptional program activated by MYC stimulates also the 
production and release of several chemokines involved in the recruitment of mast cells. Mast 
cells drive angiogenesis, and in response to IL-1β they sustain tumour growth and new blood-
vessel formation [103]. The studies of MYC and RAS family members demonstrated that 
dominant oncogenes trigger the formation of a microenviroment that promotes the tumour (the 
intrinsic pathway).  
Studies in mouse models of pancreatic tumor have demonstrated that to induce invasive ductal 
carcinoma and pancreatic intra-epithelial neoplasia both mutated Kras and mild chronic 
pancreatitis (respectively the intrinsic and the extrinsic pathway of CRI) are required. 
In conclusion, several types of gene, such as tumour suppressor proteins, RAS and RAF and 
transcription factors, coordinate different inflammatory transcriptional programs that have in 
common the recruitment of cells of myelomonocytic origin and a link to angiogenesis. 
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Figure and legend are from: Alberto Mantovani, Paola Allavena, Antonio Sica & Frances Balkwill, Cancer-
related inflammation, Nature 2008 
Figure 10: Pathways that connect inflammation and cancer.  
Cancer and inflammation are connected by two pathways: the intrinsic pathway and the extrinsic pathway. The 
intrinsic pathway is activated by genetic events that cause neoplasia. These events include the activation of various 
types of oncogene by mutation, chromosomal rearrangement or amplification, and the inactivation of tumour-
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suppressor genes. Cells that are transformed in this manner produce inflammatory mediators, thereby generating an 
inflammatory microenvironment in tumours for which there is no underlying inflammatory condition (for example, 
breast tumours). By contrast, in the extrinsic pathway, inflammatory or infectious conditions augment the risk of  
developing cancer at certain anatomical sites (for example, the colon, prostate and pancreas). The two pathways 
converge, resulting in the activation of transcription factors, mainly nuclear factor-κB (NF-κB), signal transducer 
and activator of transcription 3 (STAT3) and hypoxia-inducible factor 1α (HIF1α), in tumour cells. These 
transcription factors coordinate the production of inflammatory mediators, including cytokines and chemokines, as 
well as the production of cyclooxygenase 2 (COX2) (which, in turn, results in the production of prostaglandins). 
These factors recruit and activate various leukocytes, most notably cells of the myelomonocytic lineage. The 
cytokines activate the same key transcription factors in inflammatory cells, stromal cells and tumour cells, resulting 
in more inflammatory mediators being produced and a cancer-related inflammatory microenvironment being 
generated. Smouldering cancer-related inflammation has many tumour-promoting effects. 
 
2.2 Cancer Related inflammation: players and mechanisms 
 
The extrinsic and intrinsic pathway of CRI converge inducing key regulatory transcription 
factors, like NF-kb and signal transducer activator of transcription-3 (STAT3). NF-κB operates 
downstream of the pathways mediated by the inflammatory cytokines IL-1β and TNF-α and of 
Toll-like receptor (TLR)–MyD88 signalling pathway. Furthermore, hypoxia conditions and  
genetic alterations of cells, like deletions, amplification or mutations, can also activate NF-kB 
in tumor cell. The NF-κB pathway is strongly controlled by inhibitors acting at various stages of 
the pathway. An example is TIR8 (SIGIRR), which can inhibit signalling acting on TLRs and 
the IL-1 receptor. In tumour cells NF-kB induces the expression of adhesion molecules, key 
enzymes in the pathway of prostaglandin synthetase (such COX-2), nitric oxide synthase 
(iNOS), inflammatory cytokines, and angiogenic factors. Moreover, in cells targeted by 
carcinogenic agents and in tumor cells, NF-kB promotes survival through induction of 
antiapoptotic agents (as BCL2). Different studies demonstrated the involvement of NF-kB in 
tumor initiation and progression in tissues like the gastrointestinal tract and the liver, in which 
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CRI typically occurs [104-106]. NF-kb and also other inflammatory transcription factors induce 
the release of inflammatory cytokines and chemokines by tumour cells. NF-kB has a role also in 
regulating tumour-infiltrating leukocytes. In particular, tumour-associated macrophages 
(TAMs), which are abundant in tumour microenvironments, have a defectively and delayed NF-
κB activation [107]. This defectively activation of NF-κB in TAMs is caused by NF-κB p50 
subunit, which negatively regulates the NF-κB pathway. P50 is also responsible for the 
protumour phenotype of these TAMs [108].  
Like NF-κB, STAT3 regulates numerous oncogenic signalling pathways [109] and it is 
important for maintenance of NF-kB activation in tumors. STAT3 is constitutively activated 
both in immune cells and in tumour cells and is involved in inhibition of apoptosis and 
oncogenesis. STAT3 is the major controller of cell survival and proliferation, through 
regulation of the expression of Mcl-1, c-Myc, Bcl-2 and Cyclin D [110]. This transcription 
factor increases the capacity of tumours to evade the immune system, suppressing the immune 
response [111] and through inhibition of dendritic cells maturation. Finally, in the tumor 
microenvironment, the balance between IL-12 and IL-23 and so also the polarization of T-
helper subsets is regulated by STAT3.  
Tumour Necrosis Factor α (TNF α) improves tumor invasion and growth, angiogenesis, 
leukocyte recruitment and facilitates epithelial–mesenchymal transition. In addition, TNF-
deficient mice are protected from skin carcinogenesis. Moreover, TNF family members mediate 
also immune suppression.  
Together with TNF, also IL-1 affects some steps of the CRI cascade and can enhance metastasis. 
In a pancreatic islet tumor model, the inflammatory cytokine IL-1 promotes angiogenesis [112]. 
In transgenic mice, stomach expression of human IL-1β induces a spontaneous gastric 
inflammation and cancer, in correlation with early recruitment of myeloid-derived suppressor 
cells (MDSCs) [113]. IL-1β secreted by infiltrating leukocytes or malignant cells increases 
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tumor adhesiveness and invasion, angiogenesis and immune suppression, whereas IL-1ra 
negatively regulates these processes [114].  
Chemokynes recruit and activate leukocytes, above all cells of the myelomonocytic lineage. For 
example, CXCL5 and CXCL12 attract myeloid-derived suppressor cells, which are strong 
suppressors of the response of adaptive immunity to tumours and facilitate directly metastasis.  
CC-chemokine ligand 20 (CCL20) attract dendritic cells and monocytes, CCL2, CCL5 and 
CCL18 recruit TAM in tumors [115- 116]. Furthermore, CCL9 recruit immature myeloid cells, 
for example in colon cancer models, acting through its receptor, CCR1.   
A leukocyte infiltrate, varying in composition, size and distribution, is present in all tumours. 
Different studies have found that TAMs are among the most important infiltrating leukocyte 
and are involved in tumour progression. In addition to TAMs, related cell populations like 
myeloid dendritic cells, MDSCs and some types of monocytes, are involved in CRI [117]. At 
the beginning, macrophages involved in CRI are immune activated to have an antitumour 
activity, but during tumor progression they are educated to become protumoral [118]. During 
carcinogenesis, the microenvironment is dominated by growth factors and cytokines, released 
through stimulation of transcription factors mentioned above. The over production of these 
inflammatory factors provokes a switch from a tumour-inhibiting inflammatory response (Th1) 
to tumor promoting immune environment (Th2). TAMs are M0 and those with M2 phenotype 
suppress adaptive immunity, remodel tissues and promote both tumour growth and angiogenesis 
[119,120]. TAMs product macrophage-derived epidermal growth factor (EGF) or EGF family 
ligands and  the tumor-cell-synthesized CSF-1, which induce directional invasion and migration 
of tumor cells. Thus, macrophages and tumor cells rapidly migrate along collagen fibres, 
reaching tumor cells clustering around blood vessels [121] .  At the blood vessels, TAMs create 
an opening that permit the escape of tumor cells. Macrophages also produce other molecules 
that improve tumor cell invasion: osteonectin, which increases interaction between tumor cells 
and the extracellular matrix and thus migration; cathepsin proteases that modify the matrix and 
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thus release sequestered growth factors [122]; TGF-beta that promotes epithelial-mesenchymal 
transition of the invading tumor cells. TAMs accumulate in hypoxic regions of tumors in which 
hypoxia activates a pro-angiogenic program. The pro-angiogenic protein vascular endothelial 
growth factor (VEGF) and related molecules contribute to monocytes recruitment into primary 
tumours and in the metastatic niche [123,124]. In turn, the recruited leukocytes trigger an 
indirect pathway of angiogenesis, inducing secretion of pro-angiogenic factors [125–127]. 
TAMs increase the blood vessels density, increasing the quantity of circulating tumor cells and 
so metastasis. 
Macrophages also mediate immunosuppression, involving MDSC, DCs and regulatory T cells. 
TAMs can express human leukocyte antigens (HLA) such as HLA-C, and HLA-G, HLA-E, or 
soluble forms that block the activation of a subsets of T cells and natural killer (NK) cells. 
Finally, tumor infiltrating leukocytes induce the activation of the same transcription factors 
promoting their infiltration in tumor, resulting in an elevated production of inflammatory 
mediators that induce the CRI development.  
 
2.3 Cancer-related inflammation and adaptive immunity 
 
The malignant transformation involves the acquisition of epigenetic and genetic modifications 
that characterize the transformed cells. These modifications can be recognized by innate and 
adaptive immune mechanisms that protect the host against carcinogenesis. According to the 
theory of immune surveillance, the immune system surveys the body looking for tumor-
associated molecules, eliminating many emerging tumors. The immune surveillance activity is 
one of the three phases of the immunoediting: elimination (immunesurveillance), equilibrium, 
and escape [128]. 
The innate immune response, which involves the inflammatory cascade, drives the beginning of 
adaptive immune responses. MyD88 is the adaptor protein of the Toll Like Receptor (TLR) 
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involved in innate immune responses. MyD88 is involved in oncogene-induced cell intrinsic 
inflammation and in cancer-associated extrinsic inflammation, and as such MyD88 contributes 
to skin, liver, pancreatic, and colon carcinogenesis, as well as sarcomagenesis. In contrast, in 
specific contexts MyD88 can promote the antitumor adaptive immunity [129]. 
In a clinically overt neoplasia the adaptive immune responses are suppressed by the activation of 
multiple pathways. The activation and differentiation of dendritic cells (which promote the 
adaptive immune responses), are blocked by signals (like IL-10) abundant in the tumour 
microenvironment. Moreover, regulatory T cells, which suppress both innate and adaptive 
immune responses, are often present in tumors. MDSCs, which as TAMs are strong suppressor 
of antitumour immunity, proliferate in tumour-bearing hosts [130,131]. 
 Thus, in established tumours, in a high inflammatory context, there are multiple pathways that 
suppress effectively antitumour immunity. 
   
2.4 Cancer-inhibitory inflammation 
 
Although many studies showed that inflammation promotes tumor, there are also cases in which 
inflammation is not associated with cancer. For example, psoriasis does not enhance skin cancer 
thanks to the massive presence in skin of antitumoral M1 macrophages which balance the 
activity of the M2 TAMs. In certain contexts, inflammatory cells can destroy tumour cells. For 
example, TAMs in pancreatic tumours and in a subset of breast tumours, eosinophils in colon 
tumours and inflammatory tissue in bladder carcinoma are associated with better prognosis [132-
134]. Furthermore, the treatment of various tumors with inflammatory cytokines like IFN-α, IL-2 
and TNF-α induces significant benefits. [135-136].  
A key regulator factor in the interplay between good inflammation and tumour promoting 
inflammation is NF-kb, which can regulate macrophage M1-M2 polarization. There are also 
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others factors involved in the regulation of this balance, like the tissue type. For example, in a 
skin tumour model, NF-κB over expression inhibits invasive epidermal neoplasia, whereas the 
interruption of NF-κB pathway inhibits the development of experimental liver and colon 
cancers. Moreover, studies of William Coley at the end of the nineteen century and recent 
studies have shown that bacterial infection in patients with tumour correlated with a better 
prognosis, as for example, the patients with bladder cancer treated with  Mycobacterium bovis 
bacillus. These infections induce an adaptive immune response against tumor. 
Experiments of treatment (chemotherapy and radiotherapy) of induced mouse breast cancers 
have shown that dying tumoral cells release HMGB1, a chromatin regulator protein and an 
inflammatory regulator, which drives a protective immune response. This regulation occurs in a 
TLR4 dependent-manner. Indeed, when tumours were developed in mutant TLR4 mice, the 
efficacy of therapy was reduced. In addition, human patients with breast mutated for TLR4 have 
a higher incidence of metastasis. 
Thus, in determined conditions, the inflammatory antitumor response can prevail on the 
protumor inflammation. 
 
3. The pentraxin superfamily 
 
Innate immunity constitutes the first line of defence against microorganisms and is also 
important for the activation and regulation of adaptive immunity and for the maintenance of 
tissue repair and integrity [137]. 
Pentraxins are a superfamily of evolutionarily conserved proteins that, as component of the 
humoral arm of the innate immune system, play an important role in resistance against 
pathogens. Pentraxins are proteins of the acute phase of inflammation and are characterized by 
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a particular pentraxin domain of 200 amino acid in their C-terminal region, containing 
a “pentraxin signature” (HxCxS/TWxS, where x is any amino acid) ( figure 11).   
Based on this primary structure it is possible to distinguish short pentraxins, as the reactive-C 
protein (CRP) and serum amyloid P (SAP), and the long prentraxins, like PTX3. Pentraxins are 
conserved among the species during evolution from arachnids and insects to mammals. 
 
Figure and legend are from: Cecilia Garlanda, Barbara Bottazzi, Antonio Bastone, and Alberto Mantovani, 
Pentraxins at the Crossroads Between Innate Immunity, Inflammation, Matrix Deposition, and Female Fertility, 
Annu. Rev. Immunol. 2005 
 
Figure 11:  Short and long pentraxin structure. CRP and SAP belong to the short pentraxin subfamily and, like 
all pentraxins, are characterized by the presence of the pentraxin signature (HxCxS/TWxS, where x is any amino 
acid) in the 200 amino acid-long C-terminal domain. The Nterminal domain, typical of long pentraxins, like PTX3, 
is not conserved among the members of this subfamily.  
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3.1 The long pentraxin PTX3 
 
3.1.1 Gene and protein structure and regulation 
 
PTX3 is the archetype of the long pentraxin subfamily, characterized by a long N-terminal 
domain, associated with the C-terminal pentraxin-like domain. PTX3 was identified in the 
1990’s as a gene induced by cytokines in fibroblasts and endothelial cells [138,139]. Both the 
murine and the human PTX3 genes are localized on chromosome 3 (3q25 in human) and are 
constituted by 3 exons. The first two exons code, respectively, for the leader peptide and for the 
N-terminal domain of the protein, whereas the last exon codes for the C-terminal pentraxin 
domain. In the proximal promoters of PTX3 genes, which are conserved among human and 
mouse, there are the binding sites for several transcriptional factors (like NF-kB, Pu1, AP-1 and 
SP1) ( figure 12) [140] that regulate PTX3 expression in different contexts. In particular, AP-1 
regulates the basal PTX3 transcription, while the response to the proinflammatory cytokines 
TNF-α and IL-1β is mediated by NF-κB [140,141]. In contrast, in alveolar epithelial cells TNF-
α induces PTX3 production in a NF-kB independent manner and in, through the JNK pathway 
(142), while in endothelial cells high-density lipoproteins induce PTX3 production via 
PI3K/Akt activation [143]. The long pentraxin PTX3 is a multimeric glycoprotein characterized 
by a protomer of 381 amino acids including 17 amino acids for a signal peptide. The primary 
sequence of PTX3 is conserved during the evolution, suggesting the great importance of the 
functional role of PTX3 and of the structure/function relationships [144]. PTX3 has 203 amino 
acid in the C-terminal domain, homologous to the short pentraxins CRP and SAP, and has also 
a unique N-terminal domain, that is unrelated to any known protein. A three-dimensional model 
of PTX3 C-terminal domain has been built based on CRP and SAP crystallographic structures. 
This model showed that PTX3 pentraxin domain adopts a β-jelly roll topology. At Asn220 
PTX3 has a single N-glycosylation site. This glycosidic site is occupied by complex-type 
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oligosaccharides, mainly sialylated and fucosylated biantennary sugars with just a minor 
fraction of tetra- and triantennary glycans [145]. PTX3 has a complex quaternary structure with 
protomer subunits assembled into oligomers of high order stabilized by disulfide bonds [146]. 
Site directed mutagenesis and mass spectrometry analyses of the recombinant protein show that 
human PTX3 is composed by octamers. The PTX3 N-terminal region has three cysteine 
residues at position 47, 49, and 103, that form the three inter-chain disulphide bonds that 
support the tetramer formation. Each octamer is made by two tetramers linked together through 
additional inter-chain bridges binding the two cysteines that are located at position 317 and 318 
in the C-terminal domain. Small Angle X-ray Scattering (SAXS) and Electron Microscopy 
(EM) showed that the eight subunits of PTX3 protein fold into an elongated structure with a 
large and a small domain that are interconnected by a stalk region. The asymmetric shape of the 
molecule and this oligomerization state is unique amongst pentraxins.  
 
Figure 12: PTX3 proximal promoter transcription factor binding sites among human and mouse 
The figure show the putative sites of binding of transcription factors on PTX3 promoter conserved among human 
and mouse. 
  
PTX3 is produced by different cell types (i.e.  monocytes, macrophages, dendritic cells, alveolar 
epithelial cells, uroepithelial cells, endothelial cells, chondrocytes, fibroblasts, and adipocytes) 
after stimulation by inflammatory signals such as TLR agonists, cytokines (e.g. TNF-α, IL1-β) 
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microbial moieties (e.g. OmpA, LPS, lipoarabinomannans) or microorganisms [147-149]. IFN-γ 
inhibits PTX3 production by monocytes, macrophages and dendritic cells, reducing both gene 
transcription and the transcript stability itself [150,151]. PTX3 induction by LPS is increased by 
IL-10. Enzymatically modified and oxidized low-density lipoproteins (ox-LDL) induce PTX3 
production in human primary vascular smooth muscle cells (SMCs) and in endothelial cells 
(ECs). Glucocorticoid (GC) hormones also induce PTX3 production in non hematopoietic cells 
(like endothelial cells and fibroblasts), but inhibit PTX3 production in haematopoietic cells (like 
macrophages and dendritic cells) [152]. The GC receptor in haematopoietic cells interferes with 
the pathways of NF-κB and AP-1, whereas, in non-haematopoietic cells, it acts as a 
transcription factor. 
In addition, PTX3 is stored in specific neutrophil granules, ready to be released in response to 
TLR agonists or microorganisms [153]. PTX3 messenger is not expressed in mature neutrophils 
but is confined to immature myeloid cells. PTX3 secreted partially localizes with neutrophil 
extracellular traps (NETs) that are generated upon neutrophil stimulation. Considering the high 
number of neutrophils in circulation, the PTX3 associated to neutrophils represents the major 
source of PTX3 covering a temporal window preceding the production dependent on gene 
expression. Most recently, PTX3 expression in uroepithelial cells was also reported. After 
stimulation with uropathogenic Escherichia coli (UPEC) PTX3 expression increased rapidly  in 
a Toll-like receptor 4 (TLR4)- and MyD88-dependent manner [154].  
 
3.2. PTX3 and complement 
 
PTX3 can recognize and bind different ligands, as the component of the complement C1q, the 
main activator of the classical complement pathway [155]. The interaction between the globular 
head of C1q and PTX3 occurs in a calcium dependent-manner and leads either to inhibition or 
activation of the complement cascade. The interaction between plastic-immobilized PTX3 and 
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C1q induces the activation of the classical cascade of the complement and also the deposition of 
C3 and C4. Instead, the interaction between PTX3 and C1q in fluid phase inhibits the classical 
complement activation cascade through the competitive blocking of the relevant interaction 
sites. Furthermore, PTX3 binds at multiples sites the Factor H (FH), that is the main soluble 
regulator of complement alternative pathway, increasing the activity of FH itself and thus 
limiting an exacerbated activation of the complement cascade [156]. 
Finally, PTX3 interacts with C4b-binding protein (C4BP), which inhibits complement 
activation, helping the factor I in the inactivation and cleavage of C4b [157]. This interaction 
enhances C4BP recruitment on extracellular matrix and late apoptotic cells, suggesting that the 
C4BP recruitment by PTX3 may prevent an excessive local activation of the complement that 
would lead to inflammation and tissue damage.  
PTX3 interacts with mannose-binding lectin (MBL), ficolin-1 and ficolin-2, that are three 
members of the lectin pathway. The complex MBL/PTX3 recruits C1q, enhances the 
phagocytosis of the pathogen and enhances also the deposition of C3 and C4 on Candida 
albicans. Similarly, immobilized PTX3 is able to trigger ficolin-1-dependent activation of the 
lectin complement pathway.   
 
3.3 PTX3 in host defence  
 
PTX3 binds a large spectrum of microorganisms, like fungi, viruses and bacteria. In particular, 
PTX3 binds Pseudomonas aeruginosa [158] zymosan and Paracoccidioides brasiliensis [159], 
conidia from Aspergillus fumigatus and Salmonella typhimurium [160], Uropathogenic 
Escherichia Coli (UPEC) [154], human and murine cytomegalovirus [161], and some strains of 
influenza virus [162]. 
Ptx3 -/- mice are more susceptible to invasive pulmonary aspergillosis, in fact they show higher 
mortality than wild-type mice. This phenotype is reverted by treatment with recombinant PTX3 
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that induces a protective Th1 response, as further demonstration that PTX3 has a role in the 
tuning of immune responses. The phagocytes that are deficient for PTX3 show a defective 
clearance and recognition of A. fumigatus. In accord to this, treatment with PTX3 reverses the 
phenotype, revealing the opsonic activity of PTX3 [163]. The phagocytosis of A. fumigatus 
conidia is increased by PTX3 through interaction with FcγRs [164,165]. This interaction 
triggers CR3 (CD11b/CD18) activation, promoting the phagocytosis of the pathogens opsonised 
by C3. Moreover, PTX3 facilitates also the recognition of P. aeruginosa by neutrophils. PTX3 
maintains this prophagocytic effect in C1q-deficient mice but not in FcγR- and C3- deficient 
mice, suggesting that, the increase of phagocytosis of P. aeruginosa opsonised by PTX3 
depends on the interplay between FcγRs and complement. PTX3 has therapeutic activity in a 
murine model of chronic P. aeruginosa lung infection that is a major cause of mortality and 
morbidity in cystic fibrosis patients. The bacterial lung colonization and the inflammatory 
response caused by the infection were reduced by treatment with recombinant PTX3. 
Recently, PTX3 was identified as the first Pattern Recognition Molecules (PRM) essential for 
resistance against infection in the urinary tract induced by UPEC. In uroepithelial cells UPEC 
induce a rapid PTX3 expression through the pathway of Toll-like receptor 4 (TLR4)- and 
MyD88. In turn, PTX3 binds UPEC, enhancing their ingestion. In PTX3-deficient mice the 
defective recognition of UPEC is associated with elevated inflammation and tissue damage, 
proving the fundamental role of PTX3 in defence against urinary tract infections [154]. In 
human with urinary tract infections, PTX3 is in bladder sections and its systemic levels 
correlates with the clinical parameters of disease severity. 
PTX3 can also amplify the inflammatory response, interacting with the Outer membrane protein 
A of K. pneumoniae (KpOmpA) in a complement dependent-manner. PTX3 binds both murine 
and human cytomegalovirus (MCMV), reducing infectivity in dendritic cells, in vitro. PTX3 
binds also influenza virus (H3N2), of both human and murine, through an interaction between 
the viral haemagglutinin glycoprotein and the residue of sialic acid present on the glycosidic 
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moiety of PTX3. PTX3 has a range of antiviral activities, including inhibition of viral 
neuramidase activity, inhibition of hemagglutination and neutralization of virus infectivity. In 
contrast, PTX3 is inefficient against both pandemic and seasonal H1N1 influenza [166]. 
 
3.4 PTX3 and polymorphisms 
 
The single-nucleotide polymorphisms (SNPs) of PTX3 gene are associated to different clinical 
conditions, above all in innate resistance to infections. PTX3 SNPs correlate with the risk of P. 
aeruginosa infections in cystic fibrosis patients, increased susceptibility to pulmonary 
tuberculosis, and with severe urinary tract infections [167,168]. Moreover, PTX3 
polymorphisms correlated with protein levels and susceptibility to A. fumigatus infection in two 
cohorts of patients after bone marrow transplantation. PTX3 plasma levels are associated with 
three common genetic SNPs (rs2305619, rs3816527 and rs1840680), which may alter mRNA 
stability and consequently reduce PTX3 expression and decrease clearance and phagocytosis 
and of A. fumigatus [169]. The influence of PTX3 genetic variants was assessed also in acute 
myocardial infarction (AMI) [170]: different haplotypes of PTX3 correspond to different levels 
of PTX3 in plasma, which are correlated to all-cause death subsequent to AMI. Finally, genetic 
variants of PTX3 associated with primary graft dysfunction after lung transplantation are 
associated with increased PTX3 plasma levels [171]. 
 
3.5 PTX3 in inflammation 
 
PTX3 specifically binds P-selectin through its N-linked glycosidic moiety and endogenous 
PTX3 produced and released from haematopoietic cells or administration of PTX3 triggers a 
negative loop feedback that prevents an excessive recruitment of neutrophils by P-selectin in a 
mouse models of pleurisy, acute lung injury (ALI), acute kidney injury and mesenteric 
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inflammation [172,173]. Indeed, PTX3 produced by haematopoietic cells works locally to 
regulate inflammation and reduce neutrophil recruitment. 
A recent study has shown that PTX3 is involved in acute renal injury. In mice with renal 
ischemia-reperfusion injury, the lack of PTX3 enhanced postischemic acute kidney injury 
leading to tubular atrophy and interstitial fibrosis, whereas PTX3 recombinant injection 
prevented postischemic kidney injury [174]. PTX3 can modulate inflammation in 
atherosclerosis and acute myocardial infarction [175]. In mice, PTX3 is rapidly produced during 
acute myocardial ischemia and in PTX3-deficient mice, myocardial damages are increased, 
showing a cardio protective role for PTX3. In PTX3-deficient mice a higher deposition of C3 
has been observed, maybe caused by the missing interaction between PTX3 and factor H, which 
avoids an exacerbated activation of the complement. Moreover, in apolipoprotein E-deficient 
mice with atherosclerosis, the lack of PTX3 is associated with elevated aortic lesions, increased 
number of macrophages within the plaque and an enhanced inflammation in the vascular wall. 
In contrast to all the protective effects, in a mouse model of intestinal ischemia, the absence of 
PTX3 is accompanied by decreased tissue inflammation and lethality [176]. 
In the cumulus oophorus complex (COC) PTX3 is localized in the viscoelastic hyaluronan 
(HA)-rich matrix that forms around the oocyte [177]. PTX3 interacts with inter-α-trypsin 
inhibitor (IαI) and TSG-6, two molecules required for the incorporation into the matrix of the 
newly synthesized HA, an essential step for the organization and the stabilization of the matrix 
of cumuli. PTX3-deficient mice, because of the cumulus matrix instability, display a severe 
deficiency in female fertility.  
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3.6 PTX3 and cancer 
In the context of cancer, PTX3 can be produced by tumor cells and stromal cells, such as 
leukocytes and endothelial cells. In vivo studies show that PTX3 can be protective against 
tumors.  
PTX3 octamer has two binding sites for fibroblast growth factor 2 (FGF2) [178], which induces 
proliferation of endothelial cells, chemotaxis and in vivo neovascularization. Both FGF2 and 
PTX3, are produced by components of the vessel wall (as smooth muscle cells and endothelial 
cells) during inflammation. In murine melanoma B16-F10 cells, PTX3 inhibits FGF2-driven 
proliferation and stops the downstream FGFR signaling [179]. The overexpression of PTX3 in 
TRAMP-C2 cells (that are derived from a mouse model of prostate cancer) grafted in 
immunodeficient athymic male mice, inhibits their angiogenic and tumourigenic effects. In 
primary prostate human adenocarcinoma patients, PTX3 expression is lost in high-grade 
prostatic intraepithelial neoplasia [180].  Unpublished data of our laboratory showed that PTX3-
deficiency, is associated with increased susceptibility to 7,12-dimethylbenz [α] 
anthracene/terephthalic acid (DMBA/TPA) and 3-Methylcholanthrene (3-MCA) in 
carcinogenesis (respectively epithelial and mesenchymal). In PTX3 knockout mice 
Complement activation, CCL2 production and tumor-promoting macrophage recruitment were 
improved. 
Furthermore, in human esophageal squamous cell carcinoma, PTX3 is epigenetically down-
regulated through promoter hypermethylation [181]. In contrast, in specific tumours PTX3 is a 
potential novel biomarker of cancer related inflammation, such as in gliomas [182] and lung 
carcinoma [183]. 
Togheter, all these data suggest that PTX3 is potentially involved in cancer development. 
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Figure and legend are from: Bottazzi, B., Doni, A., Garlanda, C. & Mantovani, A. An integrated view of humoral 
innate immunity: pentraxins as a paradigm. Annual review of immunology 2010. 
Figure 13: Cellular sources and functions of the long pentraxin PTX3.  
PTX3 is produced by phagocytes (PMN, MΦ, myeloid DC), fibroblasts, SMCs, ECs and, to a lesser extent, by 
epithelial and mesenchymal cells, upon stimulation with microbial moieties (TLR agonists) or primary 
inflammatory cytokines (IL-1, TNF); IL-10 acts as a costimulus for proinflammatory stimuli. Once released, PTX3 
participates (i) in innate immune responses to fungi, bacteria, and viruses, through complement activation and 
regulation, microorganism opsonization, viral neutralization; (ii) in inflammatory responses, by modulating 
complement activation, by participating in the clearance of apoptotic cells, and possibly by other undefined 
mechanisms. PTX3 also participates in extracellular matrix deposition and angiogenesis.  
 
 
 
 50 
Aims of the thesis 
 
The long Pentraxin PTX3 has been shown to be rapidly induced upon inflammatory stimulation 
in different cell types. In particular, mononuclear phagocytes and endothelial cells have been 
shown to be major PTX3 producers in the context of acute inflammatory responses. In agreement, 
increased PTX3 levels are associated to the severity of different pathological conditions in 
humans, ranging from acute myocardial infarction to autoimmune diseases and infections. In 
animal models PTX3 deficiency leads to increased susceptibility to infections, excessive 
inflammation and tissue damage in sterile conditions and increased susceptibility to cancer.  
After the fast induction in response to inflammation, PTX3 expression is rapidly deregulated.  
These data indicate that a fine tuning of PTX3 expression is essential in innate responses to 
pathogens and to keep under control PTX3-dependent modulation of the inflammatory response 
in sterile tissue damage, including cancer.  
Thus, the general aim of this study was to gain insight into the genetic and molecular 
mechanisms at the base of regulation of PTX3 expression in basal condition, during 
inflammatory responses and in cancer.  
 
Specific aims were: 
Aim 1- Identification of the regulatory elements involved in the modulation of PTX3 expression 
both in basal and in inflammatory conditions and gain insight into their mechanisms of action.  
 
Aim 2- Investigation of the potential regulatory role of miRNAs in the  modulation of PTX3 
expression during  inflammatory responses acting by direct and indirect mechanisms.    
 
Aim 3- Analysis of the regulation of PTX3 expression by epigenetics modifications in cancer. 
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MATERIALS AND METHODS 
Prediction of cis-regulatory regions. 
The bioinformatics tool Genomic  Regions Enrichment of Annotations tools (GREAT) 
assigns biological meaning to a set of non-coding genomic regions by analyzing the annotations 
of the nearby genes. Thus, it identifies the cis functions of sets of genomic regions: putative 
enhancer.  
Analysis of the conserved regions among the species. 
The ECR Browser analyzes Evolutionary Conserved Regions (ECRs) in genomes among several 
sequenced species. 
The browser aligning the sequence of the one selected genome with others in a pairwise fashion, 
creating a conservation profile, which can be graphically displayed for any locus of the selected 
genome. ECRs are identified as regions of high sequence identity against a neutrally evolving 
background. By scanning the pairwise alignments, the browser detects sequence elements of 
significant length that are conserved above a certain level of sequence identity between the two 
genomes and highlights them as ECRs. 
 
Cell purification, culture and transfection. 
Human studies were approved by the ethical committee of Humanitas Clinical and Research 
Center (Milan, Italy). Human monocytes were obtained from buffy coats of healthy donors by 
two-step gradient centrifugation, first by Histopaque-1077 (Sigma-Aldrich) and then by Percoll 
(GE Healthcare). Residual T and B cells were removed from monocyte fraction by plastic 
adherence. Monocytes were cultured in RPMI-1640 medium supplemented with 10% FBS and 
they were differentiated to macrophages by adding 100 ng/mL M-CSF. Macrophages were 
stimulated or not with 100 ng/mL LPS for indicated times. 
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 The 8387 human fibrosarcoma cell line (ATCC) were cultured at 37ºC with 5% CO2 in RPMI 
supplemented with 10% FBS, 2 mM L-glutamine, and antibiotics (all reagents from Lonza). The 
HEK293T cell line constitutively expressing the SV40 large T antigen (ATCC) was cultured at 
37ºC with 5% CO2 in DMEM (Lonza) supplemented with 10% FBS, 2 mM L-glutamine, and 
antibiotics.  
For mimic transfection, 8 x 10
4
 8387 cells were plated in complete medium without antibiotics in 
24-well tissue culture plates and transfected 24 h later by lipofectamine 2000 reagent 
(Invitrogen). miR mimics and respective scramble controls were added to each well to 100 nM 
final concentration. 
Colorectal cancers (CRC) can be genetically classified based on mutations of mismatch repair 
genes, which are associated the microsatellite instability. Thus CRCs may be distinguished in 
microsatellite stable (MSS) or microsatellite instable (MSI). Six human CRC cell lines were 
utilized in this study, 3 CRC MSS cells (HT29, SW480, SW620) and 3 CRC MSI cells (RKO, 
SW620, LOVO) (from American type culture collection (ATCC). As the normal control for 
RNA expression in CRC cells, we used Human Colonic Epithelial Cell line (HCoEpiC) (from 
ScienceCell Research Laboratories). The CRC cell lines were cultured in RPMI medium 
supplemented with 10% fetal bovine serum and 1% ultraglutamine at 37°C in a humidified 5% 
CO2 incubator. The HCoEpiC cell lines were cultured in Colonic Epithelial Cell Medium 
(CoEpiCM, Cat. No. 2951). When specified, cells were treated with the epigenetic modifier 5-
aza-2’-deoxycytidine (5-Aza-dC, 15 μmol/mL) (A3656-5MG Sigma-Aldrich ) for 72 h and with 
Trichostatin A (TSA, 150nm/mL) (T8552-1MG Sigma-Aldrich) for 48 h. The medium 
containing 5-Aza-dC was renewed every 24 h. Then cells were washed with PBS and stimulated 
with TNFα 20 ng/mL or IL-1β 20 ng/mL for 4 h or 24 h to analyse PTX3 mRNA and protein 
expression, respectively. 
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Real time RT-PCR (RT-qPCR) analysis. 
Total RNA was extracted using the TRIzol method according to the manufacturer’s instructions 
(Ambion). RNA purity and concentration were evaluated using NanoDrop 1000 
spectrophotometer (Thermo Scientific). 1 μg of total RNA from each sample was reverse 
transcribed using the high capacity cDNA Reverse Transcription kit (Applied Biosystems), 
according to the manufacturer’s protocol. PTX3 and Erp18 gene expression was quantified by 
RT-qPCR performed in triplicate in the presence of the SYBR green PCR master mix (Applied 
Biosystems) and specific oligonucleotides 
(PTX3: FW:5’-CGAAATAGACAATGGACTCCATCC-3’; REV:5’-GCAGGCGCACGGCGT-
3’). RT-qPCR data were analysed with SDS 2.2.2 software (Applied Biosystems) and 
normalized on the expression of GAPDH expression (FW: 5’-
AACAGCCTCAAGATCATCAGC-3’; REV: 5’-GGATGATGTTCTGGAGAGCC-3’). 
According to the manufacturer instructions, TaqMan microRNA Human Assays were used to 
synthesize cDNA from 45 ng RNA using individual miR-specific RT primers and to amplify by 
qPCR each generated cDNA with sequence-specific primers in triplicate. The ubiquitous small 
nuclear U6, which showed stable expression across the time and the conditions tested, was 
chosen as the internal control for all of the experiments. RT-qPCR reaction was conducted using 
the 7900HT Fast Real-Time PCR System (Applied Biosystems). Thermal cycler conditions were 
the following for mRNA analysis: 95 °C for 20 s, 40 cycles of 95 °C for 1 s and 60 °C for 20 s. 
An initial step at 55°C for 2 min was added for miR expression analysis. 
 
ELISA assay. 
PTX3 protein released by 8387 cells in cell-free supernatants was quantified by home-made-
ELISA. In brief, 96-well ELISA plates (Thermo Scientific) were coated with 100 µg of anti-
PTX3 mAb MNB4 and incubated ON at 4°C. Nonspecific binding sites were saturated with 250 
µL of 5% dry milk (2 h at RT) prior the addition of purified human recombinant PTX3 standards 
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(from 75 pg/mL to 2.4 ng/mL) and unknown samples diluted in PBS and 2% BSA (Sigma-
Aldrich). After 2 h at 37°C, 100 ng biotin-conjugated rabbit polyclonal anti-PTX3 was added to 
each well. Plates were incubated for 1 h at 37°C and streptavidin-peroxidase (Biospa) was added, 
followed by the addition of the TMB liquid substrate system (Sigma-Aldrich). After each step, 
plates were extensively washed with PBS containing 0.05% Tween-20 (Merck Millipore), also 
used for reagent dilution.  
 
Chromatin immunoprecipitation.  
Briefly, 12x10
6
 cells were used for each ChIP. Cells were cross-linked for 10 minutes at room 
temperature using 1% formaldehyde. Cross-linking was quenched by adding glycine to a final 
concentration of 0.125M. The cells were then collected, resuspended in lysis buffer (5mM PIPES 
pH 8, 85mM KCl, 0.5% NP40 and protease inhibitors), and incubated on ice for 30 min. before 
proceeding with sonication to generate 200−400bp fragments. The efficiency of sonication was 
assessed with agarose gel electrophoresis. Chromatin samples were pre-cleared for 1 hour with 
protein-G beads and then immunoprecipitated overnight at 4°C with 5 μg of the following 
specific antibodies:  anti-H3 (Abcam, ab1791), anti-H3K27ac (Abcam code, ab4729), anti-
H3K4me3 (me, methylation; Active Motif code 39159), anti-H3K4me1 (Abcam code, ab8895), 
anti-H3K27me3 (Millipore-Upstate code, 07–449) and anti-NFκB p65 (RelA) (Millipore-Upstate 
code, 17–10060), anti-Pol II (N-20) (Santa Cruz biochemistry sc-899), anti-EZH2 (Millipore), 
anti SUZ12 (Millipore) and  rabbit IgG (Millipore; 12–370) was used as negative control. After 
incubation, the immunocomplexes were bound to protein-G beads for 2 hours and subsequently 
washed with low-salt wash buffer (0.1% SDS,  2mM EDTA, 20mM Tris HCl pH8, 1% Triton X-
100, 150mM NaCl and protease inhibitors), high-salt wash buffer (0.1% SDS, 2 mM EDTA, 
20mM Tris HCl pH8, 1% Triton x-100, 500mM NaCl and protease inhibitors), and TE buffer. 
Immunocomplexes were then eluted in elution buffer (1% SDS, 100mM NaHCO3) and cross-
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linking reverted overnight at 65°C. Samples were then treated with proteinase K, and then the 
DNA was purified with QIAquick PCR purification kit (Qiagen). 
Quantitative real-time PCR was performed in triplicate by using the following primers: PTX3 
Exon 2 (region 1): forward 5’-GAG CTA CAT AAC CGG CGA-3’, reverse 5’-GCC AAG TTG 
CAG CCC GTT CC-3’; PTX3 exon 2 (region 2): forward 5’-GGA ACG GGC TGC AAC TTG 
G-3’, reverse 5’-GTC CCA TTC CGA GTG CTC C-3’; PTX3 exon 2 (region 3): forward 5’-
GCA CTC GGA ATG GGA CAA GC-3’, reverse 5’-CGC GCA CGG CCT CGC CAG-3’; 
PTX3 exon 2 (region 4): forward 5’-CTG GCG AGG CCG TGC GCG-3’, reverse 5’-CCT CTA 
GCA CCG CGG CCA G-3’; PTX3 exon 2 (region 5): forward 5’-GGG CGC GCC CTG GCC 
GCG-3’, reverse 5’-GTG GGA GGT CCC GGC CCC-3’; PTX3 exon 2 (region 6): forward 5’-
GGG GAA GCT TTC ATG GGA AGC-3’, reverse 5’-CCG CCT TGT ATG GTG TGC CTG-
3’; PTX3 exon 2 (region 7): forward 5’-CAC AGT CTT GAA ATA GAC GTC-3’, reverse 5’-
GAA GAC GTG GAA ATC CCT AAC-3’; PTX3 promoter (region 1): forward 5’-TGT CAT 
AGG CCG GGT GAG G-3’, reverse 5’-CCG CCA CAC CCA GTT AAT-3’; PTX3 promoter 
(transcription factors binding site (TFBS) region): forward 5’-TGG CAC TGC GGT AAC GGG 
A-3’, reverse 5’-CCT CCA ATT AAT CTG ACT GC-3’; PTX3 first enhancer: forward 5’-
TCTGTGATTTGCCCAAGAGA -3’, reverse 5’- GACAAGAAAAGAGGCCCTGG-3’; PTX3-
500 bp before first enhancer: forward 5’-GCGGTCTTTTCCCTTGGTCC-3’, reverse 5’-
CCTCAGACCCAGGAAGAGTC-3’; PTX3-500 bp after first enhancer: forward 5’-
CACAGGCGTTCATTGTC-3’, reverse 3’AACTGGGAACACGTGCCAC-3.  
 Signals obtained from the ChIP samples were normalized on signals obtained from 
corresponding input samples, according to the formula 100 × 2^ (input Ct − sample Ct).  Binding 
is expressed as percentage of enrichment respect to IgG. 
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Construct generation and luciferase reporter assay. 
The PTX3 3'-UTR was amplified from the human PTX3 coding sequence (CDS), previously 
cloned in pBlueScript vector, by PCR with the M13 primer (5’-TGTAAAACGACGGCCAGT-
3’) and the following primer 5’-GAACTAGTATGTTGTGAAACTCCACTTG-3’ containing a 
SpeI restriction site (underlined), excised by SpeI-XhoI digestion and subcloned in psiCHECK-2 
vector (Promega) (Rluc-PTX3). Site-directed mutagenesis reactions were conducted using the 
QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies), in accordance with 
manufacturer’s instructions. The following constructs were generated with mutated (underlined 
region) oligonucleotides: 
 Rluc-mut-9-PTX3 (FW: 5’-CTCCACTTGAAGCGGGGGAAAGAAACTCACACT-3’; 
 REV: 5’-AGTGTGAGTTTCTTTCCCCCGCTTCAAGTGGAG-3’), 
Rluc-mut-29-PTX3 (FW: 5’-CTAGACTTTATGCCAGCCGCCTTTCAGTTTAATGC-3’, 
 REV: 5’-GCATTAAACTGAAAGGCGGCTGGCATAAAGTCTAG-3’), 
Rluc-mut-181 (FW:5’-GTCAACTTGTCATTGCGCCGAAAGAATGAAACCTTC-3’; 
 REV: 5’-GAAGGTTTCATTCTTTCGGCGCAATGACAAGTTGAC-3’), 
All clones were sequenced and subsequently used in the luciferase reporter assay. pGV-B2 
plasmid, expressing firefly luciferase under the control of human PTX3 promoter (Accession 
number X97748), was obtained as previously reported. pRL-TK vector, that expresses renilla 
luciferase gene under an eukaryotic constitutive promoter (HSV-thymidine kinase promoter), 
was used as internal control. 
The NF-κB luciferase reporter vector from BPS Bioscience (60614) contains a firefly luciferase 
gene under the control of multimerized NF-kB responsive element located upstream of a 
minimal promoter. The NF-kB reporter is premixed with constitutively-expressing 
Renilla luciferase vector, whichserves as an internal control for transfection efficiency. 
To study the direct interaction of miR and 3’-UTR with the luciferase reporter assay, 8 x 104 
HEK293T cells were plated in 24-well plates in DMEM supplemented with 10% FBS and 2 mM 
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L-glutamine and co-transfected 24 h later using lipofectamine 2000 (Invitrogen) with 100 ng 
psiCHECK-2 (Rluc constructs) or pEZX-MT01 vectors (Luc constructs) and miR mimics or miR 
negative control (scramble; Ambion) at a final concentration of 100 nM. HEK293T cells were 
co-transfected with 300 ng pGV-B2 and 100 ng of the control vector pRL-TK, and 100 nM miR 
mimics or scramble and then stimulated or not with 20 ng/mL TNF.   
HEK293T cells were also co-transfected with 100 ng of NF-kb  reporter vector  and 100 nM miR 
mimics or scramble and then stimulated or not with 20 ng/mL TNF. After 24 h, cells were 
lysed and both firefly and renilla luciferase activities were determined using the Dual-Glo 
Luciferase Assay System (Promega) and quantified using a MultiDetection Microplate Reader 
Synergy 2 luminometer (BioTek Instruments). 
 The use of psiCHECK-2 and pEZX-MT01 vector enabled the detection of changes in the 
expression of the target gene (3’-UTR) fused to a primary reporter gene (renilla luciferase, Rluc, 
for psiCHECK-2 vector and firefly luciferase, Luc, for pEZX-MT01 vector). The second reporter 
gene (Luc for psiCHECK-2 vector and Rluc for pEZX-MT01 vector) was used as an internal 
control, allowing the normalization of primary reporter gene expression. 
Results obtained from the co-transfection of 3'-UTR constructs and mimics were expressed as 
mean ± SEM of the ratio between primary luciferase and control luciferase activities adjusted to 
1. 
Generation of PTX3-inflammatory molecular network 
PTX3-inflammatory gene network has been generated and graphically visualized with Ingenuity 
Pathway Analysis (www.ingenuity.com), according to IPA predefined settings. The IPA 
Ingenuity software uses a dataset of experimental publish data to built the interaction network of 
the selected protein, calculating the P value associated to the Fisher exact test. A list of predicted 
target genes for each miR was derived from microrna.org database, taking into account both 
conserved and poorly conserved target sites. 
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Immunoprecipitation of Ago2-bound RNA species (RIP). 
Briefly ,5 to 10 x 106 of cells for each experimental point were pelletted, washed with PBS-/- 1x 
and lysed in 300 μl of lysis buffer (150 mM KCL, 25 mM Tris PH 7.4, 5 mM EDTA, 0,5% 
NP40, 5 mM DTT, protease inhibitor cocktails (Roche), 100 U/ml Superase-In (Ambion). The 
cells were lived on ice for 30 min and then centrifuged 14000 rpm for 30 min at 4°C. The 
supernatants were incubated with Dynabeads Protein G magnetic beads (Merck Millipore) 
conjugated with anti-Ago2 (EIF2C2 monoclonal antibody, clone 2E12-1C9; Abnova) or isotype 
IgG1k control antibodies (Abnova). After the immunoprecipitations, we kept the flow-through 
which contains the Ago2 unbound fraction, labeled “left over ip”. The beads with the Ago2 
bound fraction were washed 3 times with the lyses buffer, before the direct RNA extraction with 
the TRizol. Results were expressed as fold enrichment relative to IgG1k-IP control samples. The 
miR/mRNA enrichment in the RNA-induced silencing complex was calculated according to the 
formula 2
-(CtAgo - CtIgG)
 and results were expressed as fold enrichment relative to IgG-IP control 
samples. 
  
PTX3 expression profiles in cancer 
Using Oncomine gene expression browser (www.oncomine.org) to check the level of PTX3 
mRNA in several human healthy tissue and cancer types.   
 
Tissue samples 
Patients: Paraffin-embedded tissues from oncologic Caucasian patients, who underwent 
resection surgery at Humanitas Clinical and Research Center, were examined for PTX3 gene 
epigenetic modification. The study included the following cases: 3 angiomyosarcomas, 5 
leiomyosarcomas, 5 synovial sarcomas, 5 solitary fibrous tumors, 5 chordomas, 5 gastrointestinal 
stromal tumors, 3 desmoid tumors, 6 squamous cell carcinoma,  5 high grade adenomas, 10 stage 
I colorectal cancer (CRC), 10 stage II CRC, 10 stage III CRC and 10 stage IV CRC. The 
 59 
Institutional Review Board of the Humanitas Clinical and Research Center, Rozzano, Italy, 
approved this study (ICH-99/09).  
Adenoma laser microdissection: Paraffin-embedded, hematoxylin and eosin (H&E)-stained 
slides were reviewed by a pathologist (M.N.). Six sections 5 μm thick were cut from selected 
formalin-fixed, paraffin-embedded blocks and mounted on PEN membrane glass slides (LCM 
tissue slides, Life Technologies, Monza Italy). One section from each sample was stained with 
H&E to select areas of high-grade adenoma for DNA purification. The remaining sections were 
used to collect adenoma tissue by laser capture microdissection (Leica LMD 7000). 
                
Methylated CpG Island Recovery Assay (MIRA). 
Genomic DNA from cell cultures or paraffin-embedded tissues was purified by QIAamp DNA 
Midi kit (QIAGEN) and fragmented by sonication to about 400 bp average sizes as verified on 
agarose gel. Enrichment of the methylated double-stranded DNA fraction was performed with 
the MethylCollector Ultra Kit (Active Motif), according to manufacturer's instructions. Eluted 
DNA was purified with QIAquick PCR purification kit (Qiagen). Quantitative real-time PCR 
was performed in three promoter regions containing at least 5 CpG, and on the CpG island 
divided in 7 about 120 bp regions.  Quantitative real-time PCR was performed in triplicate by 
using the following primers: PTX3 Exon 2 (region 1): forward 5’-GAG CTA CAT AAC CGG 
CGA-3’, reverse 5’-GCC AAG TTG CAG CCC GTT CC-3’; PTX3 exon 2 (region 2): forward 
5’-GGA ACG GGC TGC AAC TTG G-3’, reverse 5’-GTC CCA TTC CGA GTG CTC C-3’; 
PTX3 exon 2 (region 3): forward 5’-GCA CTC GGA ATG GGA CAA GC-3’, reverse 5’-CGC 
GCA CGG CCT CGC CAG-3’; PTX3 exon 2 (region 4): forward 5’-CTG GCG AGG CCG TGC 
GCG-3’, reverse 5’-CCT CTA GCA CCG CGG CCA G-3’; PTX3 exon 2 (region 5): forward 5’-
GGG CGC GCC CTG GCC GCG-3’, reverse 5’-GTG GGA GGT CCC GGC CCC-3’; PTX3 
exon 2 (region 6): forward 5’-GGG GAA GCT TTC ATG GGA AGC-3’, reverse 5’-CCG CCT 
TGT ATG GTG TGC CTG-3’; PTX3 exon 2 (region 7): forward 5’-CAC AGT CTT GAA ATA 
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GAC GTC-3’, reverse 5’-GAA GAC GTG GAA ATC CCT AAC-3’; PTX3 promoter (region 1): 
forward 5’-TGT CAT AGG CCG GGT GAG G-3’, reverse 5’-CCG CCA CAC CCA GTT AAT-
3’; PTX3 promoter (region 2): forward 5’- TCG AGA CCA GCC TGG CTA A-3', reverse 5'-
GCA ATG GTG CTC CCG CAT C-3' ; PTX3 promoter (transcription factors binding site 
(TFBS) region): forward 5’-TGG CAC TGC GGT AAC GGG A-3’, reverse 5’-CCT CCA ATT 
AAT CTG ACT GC-3’. PTX3 first enhancer: forward 5’-TCTGTGATTTGCCCAAGAGA -3’, 
reverse 5’- GACAAGAAAAGAGGCCCTGG-3’. 
For all samples, MIRA-enriched DNA was compared with input DNA, according to the formula 
100×2
(input Ct − sample Ct)
, normalized to the value of the positive control provided with MIRA kit 
(NBR2) and expressed as percentage of enrichment. 
 
Statistical analysis 
Data were expressed as means ± SEM of N experiments or donors, as specified. Dunnett’s post-
hoc test following a one-way ANOVA or Student’s t-test were used, as specified, to determine 
statistical changes. p ≤ 0.05 were considered significant. Statistics were calculated with 
GraphPad Prism version 5 (GraphPad Software). 
Statistical analysis was performed using the Student’s t test and the χ2 test; a value of P < 0.05 
was considered to be statistically significant. 
 
Immunohistochemistry.  
Four-μm consecutive sections were cut from the CRC Paraffin-embedded tissues and used for 
PTX3 immunohistochemistry. Sections were dewaxed in Xilol or Bioclear, then they were 
hydrated with rapid wash in Ethanol 100% , Ethanol 90%, Ethanol 70% and then in H2O. 
Antigens were unmasked in microwave oven 2 step for 5 min at 800MW in EDTA pH 8.00 
buffer 0.25 mM. Then the endogenous peroxidase was blocked for 5 min with a Peroxidized 1 
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(Biocare Medical) ready to use. Unspecific sites were blocked with Background Sniper 
(#BS966G Biocare Medical) for 15 min and tissues were incubated for two hours with Rabbit 
polyclonal  antibody anti Human PTX3 purified  (rabbit polyclonal IgG) in in  DaVinci Green 
Diluent (#PD900H Biocare Medical). MACH 4 Universal HRP-Polymer Detection (cod: 
M4U534,  Biocare Medical) was used as secondary antibody for 30 minutes. After washing, 
slides were developed with DAB (3,3’-diaminobenzidine) (Biocare Medical) and counterstained 
with Hematoxilyn. Tissues were dehydrated with ethanol, mounted with Eukitt and analysed 
with an Olympus BX61 virtual slide scanning system.  
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Result 
1. Characterization of PTX3 regulatory elements in basal conditions 
and in response to inflammatory stimuli 
 
1.1 Bioinformatics analysis revealed 2 enhancers potentially involved in the 
regulation of the long pentraxin PTX3. 
 
In order to identify regulatory elements, such as miRNAs and enhancers, that could potentially 
modulate PTX3 gene expression, we first used bioinformatics tools to screen the whole PTX3 
sequence. As shown in Figure 14, PTX3 has a promoter upstream of 3 coding sequences and a 
CpG island localizing with the second. We checked also the microRNAs that could target PTX3 
3’UTR and identified 8 different miRNAs: has-miR-9, has-miR-29a/b/c and has-miR-181a/b/c/d. 
We identified enhancer regions using raw data from Chip-seq analysis of histone modifications, 
found on Geo profiles: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE36401. We 
analysed three samples of human normal colon mucosa and 3 samples of human colon cancer. 
Using the  Genomic Regions Enrichment of Annotations Tool (GREAT), that assessed the 
functional significance of several enhancers, we found 2 putative enhancers that could regulate 
the PTX3 gene. As shown in figure 15, these putative genetic elements are located on 
chr3:156893652-156894644 (the first enhancer) 230 kb upstream the gene promoter region and 
spanning the second exon of the PTX3 gene (hg19 chr3:156,893,632-156,894,644) (the second 
enhancer), respectively.  
We then verified the conservation of these sequences among species, using ECR browser and we 
observed that the exonic enhancer was highly conserved (more than 70%), whereas the first 
enhancer was less conserved (50%) (Figure 15).  
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Since DNA methylation is involved in regulating the activity of enhancers, we also wondered 
whether CpG islands were present in these genetic elements. In order to do this, we used 
Genome Browser and the softwares Epiginomes and Methyl Primer Express v1.0, which allowed 
us to identify CpG sites and calculate their enrichment in the regions of interest.  
The analysis (Figure 15) showed that the exonic enhancer localized in a CpG island, whereas 
both the promoter and the first enhancer are CpG-poor sites. We also observed that both these 
regulatory elements shared putative binding sites for RNA Polymerase II and for transcription 
factors that characterize enhancers, including P300.      
         
  
 
Figure 14: Human Long Pentraxin PTX3  coding sequences. PTX3 mRNA is organized in 3 exons (light blue) 
and 2 introns. PTX3 second exon localized in CpG island 557 bp long.  Human PTX3 3’ UTR is the putative  target 
of  several miRNAs, including miR9, miR29 family and miR 181 family. 
  
  Exon 3 
CpG island 
3’ UTR 
hsa-miR-9 
hsa-miR-29a/b/c 
hsa-miR-181a/b/c/d 
hPTX3 
 Promoter    Exon 1    Exon 2  
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Figure 15: PTX3 putative enhancers are conserved among species.  Analysis of genome conservation among 
species of the human PTX3 gene and putative enhancer through ECR browser. The conservation rate is calculated 
by the browser comparing the sequence of the  PTX3 human gene among species: fugu, frog, chicken, opossum, dog, 
mouse, rat and Rhesus macaque, respectively.    
 
1.2 PTX3 enhancers are activated by inflammatory stimuli in the 8387 cell 
line. 
To gain insight into the activation state of the two enhancers associated to PTX3,we first 
checked the mRNA transcription levels of the gene and to determine the peak of maximum 
expression, which is  dependent on the activity of regulatory elements.  
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We analyzed PTX3 expression and production in the 8387 human fibroblast cell line, that 
produces a detectable amount of PTX3 even in basal conditions, as shown by previous results in 
our laboratory. As shown in figure 16, PTX3 expression increased in response to TNFα and IL-
1β inflammatory stimuli: PTX3 mRNA was highly expressed at 4h and it decreased at 8h and 
24h.  We  observed the highest level of PTX3 mRNA expression 4 hours after treatment with 
TNFα, whereas the protein level reached a peak 24 hours upon treatment.  
 
Figure 16: PTX3 mRNA expression and protein production in the 8387 cell line. 
A-B) Kinetic analysis by RT-qPCR of PTX3 mRNA expression (A) and protein production (B) in 8387 cells as 
measured by ELISA in the cell supernatant, in normal conditions and after 20 ng/ml TNF and IL-1β treatment. 
Results are expressed as 2^
-ΛCt
  (A) and as ng/mL (B) and as mean ± SEM (N = 4 experiments). *: p ≤ 0.05, **: p ≤ 
0.01, ***: p ≤ 0.001; Student’s t-test. 
 
To validate the activity of the putative enhancers and to characterize their functional role, we 
performed Chromatin Immune Precipitation (ChIP) assays using antibodies specific for the 
histone modifications that characterize active enhancers (H3K4me1, H3K27Ac) and inactive  
enhancers (H3K27me3). As positive control, we used antibodies specific for Histone 3 (H3), 
which is constitutively expressed. As negative control, we also checked the levels of histone 
modifications in the regions upstream and downstream the sites of interest. Regarding the first 
enhancer, we analysed 3 sites: a central region, which is the most conserved among species 
-     -     -          +    +    +          -     -     -   TNFα 
-     -      -         -     -     -          +    +     +   IL-1β 
-     -     -          +    +    +         -     -    -   TNFα 
-     -      -         -     -     -         +    +   +   IL-1β 
B A 
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(Figure 2) and 2 other regions 500 bp away from it. Concerning the second enhancer, we 
analysed 7 fragments. After cell stimulation with an inflammatory cytokine, the two regulatory 
elements switched from an inactive to an active state and this correlates with an higher PTX3 
expression. The results related to the first putative regulatory element indicated that the central 
region is the effective enhancer, since it showed high levels of active markers and low levels of 
repressor markers (figure 17). Thus, in the following analysis we did not further investigate the 
adjacent regions. The putative regulatory elements were functional enhancers in the 8387 cell 
line. 
 
Figure 17. Chromatin Immunoprecipitation of histone modifications revealed that  PTX3 have 2 enhancers. 
ChIP assay in the 8387 cell line in basal condition and 4h after stimulation with TNFα using antibodies recognizing 
H3K4me1, H3K27Ac and H3K27me3 histone modifications. Results are expressed as percentage of enrichment to 
IgG  and as a mean  ± SEM (N = 3 experiments) of values obtained according to the formula 100 × 2^ (input Ct − 
sample Ct) and then normalized on IgG.   *: p ≤ 0.05, **: p ≤ 0.01, ***: p ≤ 0.001; Student’s t-test. Each region 
analyzed with RT-qPCR is 150 bp long.  
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1.3 The PTX3 promoter is active both in basal and in inflammatory condition 
in the 8387 cell line.    
  
Given that enhancers regulate gene expression acting on the promoter,   we then analysed the 
PTX3 promoter activity in the 8387 cell line both in basal condition and upon treatment with 
TNFα. Histone signature of promoters consists of modifications associated with both 
transcriptional activation (H3K4me3, H3K9Ac and H3K27Ac) and repression (H3K27me3), 
which  are dependent on the Polycomb group complex. We analyzed 2 different regions: the first, 
called P1, that is located 500 bp before the transcription starting site (TSS) and the transcription 
factor binding site (TFBS)  region, that  is a putative binding site for several transcription factors 
and that is 20 bases upstream the TSS.  
PTX3 promoter (figure 18) was demonstrated to be active even in basal condition, but upon 
stimulation with TNFα, we observed a significant increase in the activation of the TFBS, which 
is the closest to the TSS and the most enriched in nucleosomes. 
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Figure 18.  PTX3 promoter activity increased after treatment with TNFα in the 8387 cell line. 
ChIP assay in the 8387 cell line in basal condition and 4h  after stimulation with TNFα using antibodies recognizing 
H3K4me3, H3K27Ac, H3K9Ac and H3K27me3 histone modifications. Results are expressed as percentage of 
enrichment to IgG  and as a mean  ± SEM (N = 3 experiments) of values obtained according to the formula 100 × 2^ 
(input Ct − sample Ct) and then normalized on IgG.   *: p ≤ 0.05, **: p ≤ 0.01, ***: p ≤ 0.001; Student’s t-test. Each 
region analyzed with RT-qPCR is 150 bp long.  
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1.4 Inflammatory cytokines enhance PTX3 expression improving RNA 
Polymerase II activity in a NF-kB dependent manner.  
 
The expression of PTX3, which is a protein of the acute phase of inflammation, is regulated by 
inflammatory transcription factors, including NF-kB in response to inflammatory stimuli, such as 
TNFα. To verify whether PTX3 enhancer activation was mediated by this factor, we performed a 
Chip assay for the NF-kB active subunit p65 in 8387 cells, both in basal conditions and 4 hours 
after treatment with TNFα (figure 19). As negative control, we used the exon 2 of the PTX3 gene, 
which lacks putative binding sites for this transcription factor. The result show that the 
inflammatory cytokine TNFα induced the binding of NF-kB to both the PTX3 promoter and the 
first enhancer, whereas the second PTX3 enhancer was not bound.   
Among the regulatory regions analysed, the TFBS region and the first enhancer displayed the 
highest affinity for NF-kB. 
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Figure 19:  NF-kB binds PTX3 regulatory elements in the 8387 cell line. 
ChIP assay in the 8387 cell line in basal condition and 4h after stimulation with TNFα. We analyzed PTX3 enhancer 
1 (panel 1), promoter regions (panel 2 and 3), and enhancer 2 at the end of the CpG island (panel 4) using antibodies 
anti-NF-kB (p65). Results are expressed as percentage of enrichment to IgG  and as a mean  ± SEM (N = 3 
experiments) of values obtained according to the formula 100 × 2^ (input Ct − sample Ct) and then normalized on 
IgG.   *: p ≤ 0.05, **: p ≤ 0.01, ***: p ≤ 0.001; Student’s t-test. Each region analyzed with RT-qPCR is 150 bp long.  
 
To characterize the mechanisms involved in the regulation of PTX3 expression, we performed a 
Chip assay for RNA Polymerase II (Pol II)  and for the major Polycomb group subunities 
(SUZ12 and EZH2), in 8387 cells both in basal condition and after 4h of treatment with TNFα.  
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We analyzed the putative binding sites for the enzymes, using as negative control a region of the 
PTX3 intron 1. The results show that the promoter was active in basal condition and upon 
stimulation. An increased binding of RNA Pol II was observed, in particular in the proximity of 
the TSS (panel 3 figure 20).  
The first enhancer did not bind Pol II, whereas bound SUZ12 and EZH2 in basal conditions. 
After inflammation, it lost the binding of the Polycomb complex and gained the binding of the 
RNA Pol II, thus getting active. The same results were obtained for the second enhancer, that 
bound  the RNA Pol II only after inflammatory stimulus (panels 4 and 5 in the figure 20).  
In one of the two regions considered (Panel 5, Figure 20), the RNA Pol II bound the second 
enhancer also in basal condition, but it was maintained paused by the Polycomb group. The 
stimulation with TNFα induced the loss of the Polycomb subunits and a strong increase of Pol II 
activity. 
Collectively, these results indicate that both enhancer regions are inactive in basal conditions and 
became active after stimulation with TNFα. 
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Figure 20: The Polycomb group regulates RNA Polymerase II activity in PTX3 regulatory regions. 
ChIP assay in the 8387 cell line in basal condition and 4h after stimulation with TNFα in PTX3 intron 1 control 
region (panel C), enhancer 1 (panel 1), promoter regions (panel 2 and 3), enhancer 2 at the end of the CpG island 
(panel 4 and 5) using antibodies anti-Suz12, anti-EZH2, anti –RNA Pol II. Results are expressed as percentage of 
enrichment to IgG  and as a mean  ± SEM (N = 3 experiments) of values obtained according to the formula 100 × 2^ 
(input Ct − sample Ct) and then normalized on IgG.   *: p ≤ 0.05, **: p ≤ 0.01, ***: p ≤ 0.001; Student’s t-test. Each 
region analyzed with RT-qPCR is 150 bp long.  
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2. PTX3 is directly and indirectly modulated by different miRNAs during 
inflammatory conditions. 
 
The microRNAs (miRNAs) are small RNA non coding that silence several and multiple genes 
involved in different pathway, including in inflammation and immune response.    
In order to verify the potential role of miRNAs in the regulation of PTX3 gene and the 
modulation of its network, we first confirmed that the miR 9, miR-29a/b/c and miR-181a/b/c/d, 
identified by bioinformatics softwares (Targetscan), actually targeted PTX3 3’UTR, performing 
a luciferase assay (figure 21 panels A-C). To address this point, we transfected 8387 cells with 
the mature miRNA and analysed PTX3 protein production 8h and 24h after stimulation with 
TNFα (figure 21 panel D), whereas mRNA expression was detected 4h and 8h after stimulation 
(figure 21 panel E). The results showed that miR-9, miR-29 family and miR-181 family 
significantly reduced PTX3 protein production both 8 hours and 24 hours upon stimulation with 
TNFα. Furthermore, PTX3 mRNA level was also reduced upon transfection with miR9, miR-29 
family and miR-181a and miR-181c, after inflammatory stimulus. Thus suggest that these 
miRNAs were able to degrade their target.    
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 Figure 21: miR-9, miR-29 and miR-181 regulate PTX3 
A-B-C) Luciferase reporter assay in the HEK293T cells co-transfected with the indicated luciferase constructs 
(Rluc-vectors coding the PTX3 3'-UTR sequence, mutated in the seed region of each miR) together with miR-9, 
miR-29abc, miR-181abcd mimics or the scramble control (white column). Results are expressed as mean ± SEM (N 
= 3 experiments) of the ratio between renilla luciferase and firefly control luciferase activities (RLU) adjusted to 1. 
*: p ≤ 0.05, **: p ≤ 0.01, ***: p ≤ 0.001; Dunnett’s post-hoc test following a one-way ANOVA. D) TNF-induced 
PTX3 production in 8387 cells 8 and 24 hours upon transfection with miR-9, miR-29c and miR-181c mimics or the 
scramble control. The data are shown as fold change and are obtained dividing by the scrumble and multiplying to 
100.  TNF-induced (E) PTX3 expression  at 4 and 8 h by 8387 cells transfected with miR-9, miR-29c and miR-
181c mimics or the scramble control. The data are shown as . Results are shown as mean ± SEM (N = 3-6 
experiments). *: p ≤ 0.05, **: p ≤ 0.01, ***: p ≤ 0.001; Student’s t-test. 
 
To assess whether the regulation mediated by miR-9, miR-29 family and miR-18a family could 
also be an indirect mechanism, we cloned the PTX3 promoter into a specific luciferase vector to 
analyze its activity after 24h of stimulation with TNFα in 293T cell line, which does not express 
PTX3. All the microRNA analysed, except miR-9, determined a reduction of the promoter 
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activity (figure 22 panel A).  Since the stimulation with TNFα induced the binding of NF-kB to 
the PTX3 promoter (figure 19), we transfected 293T cells with a NF-kB reporter vector, in order 
to check whether the miRNAs considered had an effect on the transcription factor activity (figure 
9 panel B). Results showed that miR-181 family and miR-29b reduced NF-kB activity.    
 
Figure 22.  miRs regulate  PTX3 promoter 
A) Luciferase reporter assay in the HEK293T cell line co-transfected with the PGV-B2 vector expressing the PTX3 
promoter sequence fused to the firefly luciferase Coding sequence and the pRL-TK vector expressing renilla 
luciferase as normalizer and with the specified miR mimics (black bars) or the scramble control (white bars) (A). 
The experiment was conducted in basal condition and upon stimulation with 20 ng/mL TNF . Results were 
expressed as mean ± SEM (N = 3 experiments) of the ratio between firefly luciferase and renilla control luciferase 
activities (L/R). *: p ≤ 0.05, **: p ≤ 0.01, ***: p ≤ 0.001; Dunnett’s post-hoc test following a one-way ANOVA. (B) 
Luciferase reporter assay in the  HEK293T cell line co-transfected with the NF-kB reporter vector expressing NF-
kB regulatory sequence fused to the firefly luciferase CDS and  the pRL-TK vector expressing renilla luciferase as 
normalizer and with the specified miR mimics (black bars) or the scramble control (white bars).  
 
Several studies showed that the innate immune response and also the inflammatory response are 
regulated by miR-9, miR-146a, miR-155 and miR132. More in details, these inflammatory 
miRNAs might modulate the inflammatory transcription factors NF-kB. We checked whether  
miR-146a, miR-155 and miR132, regulate PTX3 expression. The experiments demonstrated that 
these miRNAs downregulated PTX3 promoter activity (figure 23 panel A), acting on NF-kB 
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pathway (figure 23 panel B), and thus affecting the PTX3 promoter activity (figure 23 panel C 
and D). miR-146a, miR-155 and miR-132 did not target PTX3 3’UTR (figure 23 panel E)  
 
Figure 23. Inflammatory miRNAs indirectly regulate PTX3 expression. 
A-B)Luciferase reporter assay in HEK293T cell line co-transfected with PGV-B2 vector expressing the PTX3 
promoter sequence (A) and with NF-kB reporter vector expressing NF-kB regulatory sequence (B) fused to the 
firefly luciferase CDS and pRL-TK vector expressing renilla luciferase as normalizer and with the specified miR 
mimics (black bars) or the scramble control (white and grey bars). The experiment was conducted  upon stimulation 
with 20 ng/mL TNF 
C-D)TNF-induced  PTX3 mRNA expression , at 4h and 8h after treatment with TNFα (C),  and production (D) at 
8h and 24h after treatment with by 8387 cell lines transfected with miR-132 , miR-146a , miR-155 mimics or the 
scramble control. Results are shown as mean ± SEM (N = 3-6 experiments). *: p ≤ 0.05, **: p ≤ 0.01; Student’s t-
test. 
E) Luciferase reporter assay in the HEK293T cells co-transfected with the indicated luciferase constructs (Rluc-
vectors coding the PTX3 3'-UTR sequence) together with miR-132, miR-146a and miR-155 mimics or the scramble 
control (white column). Results are expressed as mean ± SEM (N = 3 experiments) of the ratio between renilla 
luciferase and firefly control luciferase activities (RLU) adjusted to 1. *: p ≤ 0.05, **: p ≤ 0.01, ***: p ≤ 0.001; 
Dunnett’s post-hoc test following a one-way ANOVA. 
 
Rluc-mut29-PTX3 
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In order to improve the characterization of PTX3 regulatory network, we took advantage of the 
IPA Ingenuity software (http://www.ingenuity.com/products/ipa), focusing on inflammatory 
pathways. IPA tools allow to analyze published interaction data, uncovering multi-level direct 
and causal relationships, thus including regulators that are not directly connected to targets.  
We analyzed PTX3 pathway, focusing on the interactions of PTX3 with several inflammatory 
cytokines, including IL-1β and TNFα, and the bacterial component LPS (Figure 24).  
The analysis also included the putative PTX3 regulatory miRNAs calculated with mathematics 
algorithms and validated in our study. We obtained a complex interaction network in which 
PTX3 was regulated by inflammatory cytokines, but could also regulate those cytokines. Indeed, 
the graph showed that PTX3 could indirectly regulate its own expression. PTX3, LPS and the 
cytokines analyzed, could activate TLR4 and TLR9 pathway, modulating several genes 
downstream of the TLR. Finally, the microRNAs that directly targeted PTX3 were predicted to 
regulate transcription factors, LPS and some inflammatory cytokines, as well.         
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Figure 24: PTX3 interaction pathway. 
Interaction network of PTX3 protein in inflammatory pathway extrapolated by IPA Ingenuity software. The protein 
interaction data are extrapolated to publish articles, whereas the regulation of the miRNAs are calculated by also 
mathematics algorithms.     
 
Finally, to validate the data obtained and to better define the mechanism of action of microRNAs, 
we performed a RNA ImmunoPrecipitation assays (RIP) on human resting or LPS-stimulated  
macrophages, at different time point. We used an antibodies that recognises the Ago2 protein 
and thus the RISC complex which binds the mature miR. The results show that PTX3 expression 
increased 4 hours upon stimulation and started decreasing after 6 hours. At the same time, the 
entrance of both PTX3 and the presence of the miRNAs to the RISC was observed, 6 hours upon 
stimulation (figure 25). Interestingly, in basal condition the miRNAs  had no effect on PTX3 
expression. 
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Figure 25. PTX3 is directly regulated by several miRNAs in macrophages after LPS stimulation. 
Resting macrophages and after stimulation with 100 ng/mL LPS were subjected to RIP assay by using anti-Ago-2 or 
IgG control Abs at different time points. 
A) Kinetic analysis by RT-qPCR of PTX3 mRNA expression in human  macrophage after stimulation with LPS. 
Result are  expressed as 2^
-ΛCt
 and as mean ± SEM (N = 3 experiments). *: p ≤ 0.05, **: p ≤ 0.01, ***: p ≤ 0.001; 
Student’s t-test. 
B-J) Levels of  PTX3 (B) and  miRNAs (C-J) detected in the RISC complex were determined by RT-qPCR in IP. 
Results are expressed as fold enrichment relative to the corresponding IgG control sample (mean ± SEM, N = 3 
donors). *: p ≤ 0.05, **: p ≤ 0.01, ***: p ≤ 0.001; Student’s t-test.  
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3.PTX3 regulatory mechanisms in cancer 
3.1 PTX3 expression in cancer 
 
Preclinical data obtained in PTX3 KO mice studying epithelial and mesenchymal cancerogenesis 
demonstrated that PTX3 played a key role in controlling tumor incidence. 
In order to assess whether the results obtained in the mouse could be relevant in humans we 
evaluated PTX3 mRNA expression level in human tumor tissues. We used the Oncomine 
browser and checked PTX3 mRNA expression in both mesenchymal- and epithelial-derived 
tumors. As Figure 26 shows, PTX3 mRNA expression level in normal tissues and in different 
sarcoma tumors (figure 26 panel A) [184], melanoma (figure 26 panel B) and epithelial tumors, 
like skin cancer (figure 26 panel B) [185] and colorectal cancer (figure 26 panel C) [186]. The 
data indicate that PTX3 expression is variable, depending on the type of tissue and also on the 
type of tumor. For example, sarcoma tumors analyzed displayed similar levels of PTX3 mRNA 
compared to the healthy tissue, except leiomyosarcoma, in which the level of PTX3 transcript 
was lower (figure 26, panel A column 2). Healthy epithelial tissues generally displayed low 
levels of PTX3 mRNA (figures 26 panel B and C, column 0), compared to the other tissue types 
analyzed. Moreover, the PTX3 transcript level was reduced in both skin and colon cancer 
compared to the healthy counterpart. 
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Figures adapted from Oncomine.            
Figure 26: PTX3 expression in tumors .  
A) Barretina Sarcoma Dataset: PTX3 mRNA expression was measured in 149 soft tissue sarcomas of 6 different 
subtypes and 9 normal adipose tissue (number 0: no value) specimens.                                            
B) Riker Melanoma Dataset: PTX3 mRNA expression was measured in 82 tissue of patients with 5 different 
subtypes melanoma and 5 normal epithelial tissue (number 0: no value)   
C) Hong Colorectal Dataset: PTX3 mRNA expression was measured  70 colorectal carcinoma and 12 normal colon 
samples.  
 
3.2 PTX3 is silenced in colorectal cancer cells through DNA methylation 
 
To confirm the data from Oncomine, we analysed PTX3 expression in several colorectal cancer 
(CRC) cell lines in basal condition and upon treatment with inflammatory stimuli. To  verify the 
potential role of DNA methylation as main actor involved in PTX3 silencing, we treated CRC 
A B 
C 
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cells with the DNA methylation inhibitory agent 5’AZA- 2’ deoxycytidine (5’AZA-dC). With 
this treatment, we obtained a rescue of PTX3 mRNA expression and protein production (Figure 
27), whereas  the co-treatment with DNA methylation inhibitor and inflammatory cytokines 
determined higher PTX3 level compared to the healthy colon. Conversely, the co-treatment with 
the inhibitor of the histone deacetylases Trichostatine A (TSA) and 5’AZA-dC had the same 
effects as the inhibitor of methylation alone. We also checked PTX3 mRNA expression levels in 
healthy epithelial colon cell line (HCoEpic) in inflammatory conditions with or without 5’aza-dC 
treatment (figure 27 ).  
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure adapted from Bonavita E, Gentile S., Rubino M,  et al. Accepted for publication in Cell 2015 
HCoEpiC 
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Figure 27: PTX3 expression is restored byco-treatment with 5’AZA-dC and TNFα  in CRC cell lines. 
PTX3 mRNA expression by SW480, HT29, RKO, HCT116, SW620 and normal colon epithelial cell line (HcoEpic). 
CRC cell lines were treated or not with 5’AZA-dC alone and with 5’AZA-dC and TSA in the presence of TNFα or 
IL-1β.   HcoEpic were treated with 5’AZA-dC  alone and with TNFα.  Result are  expressed as 2^-ΛCt and as mean ± 
SEM (N = 3 experiments). *: p ≤ 0.05, **: p ≤ 0.01, ***: p ≤ 0.001; Student’s t-test. 
 
We also analyzed the effect of the inhibitor of DNA methylation on PTX3 production in the 
CRC cell lines that were more responsive to 5’AZA-dC treatment (figure 28). The inhibitory 
agent together with inflammatory cytokines restored the levels of PTX3 protein, whereas 
5’AZA-dC alone had a  slight effect on PTX3 rescue.  
 
 
Figure adapted from Bonavita E, Gentile S., Rubino M,  et al. Accepted for publication in Cell 2015 
Figure 28: PTX3 protein production is restored in CRC cell lines after cotreatment with 5’AZA-dC and 
TNFα. 
PTX3 mRNA protein production by SW480, RKO and HCT116 cell lines treated or not with 5-AZA-dC in the 
presence of TNFα 20 ng/mL or IL-1β 20 ng/mL. Result are  expressed ang/ml  and as mean ± SEM (N = 3 
experiments). *: p ≤ 0.05, **: p ≤ 0.01, ***: p ≤ 0.001; Student’s t-test. 
 
We analysed PTX3 methylation in 4 CRC cell lines of different tumor stages (I-IV). As shown in 
Figure 29 (panel A) PTX3 promoter region and the second enhancer were hypermethylated, 
whereas the first enhancer was hypometylated. The treatment with the methylation inhibitor 5-
AZA-dC significantly reduced the methylation of PTX3 regulatory regions.  
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To verify if PTX3 methylation detected in CRC cells  was dependent on the tumor or on the type 
of tissue, we checked DNA methylation levels of a human epithelial colon cell line (HCoEpiC) 
(figure 29 panel B). The data showed that Human colonic ephitelial cells were hypomethylated, 
with a methylation levels lower than 5% in promoter region and corresponding to the CpG island 
(second enhancer), whereas the first enhancer was completely unmethylated.  
                            
Figure adapted from Bonavita E, Gentile S., Rubino M,  et al. Accepted for publication in Cell 2015 
Figure 29: PTX3 is hypermethylated in CRC cell lines. 
A) Analysis by MIRA of the percentage of methylation enrichment of PTX3 regulatory regions in CRC cell lines 
with and without treatment with 5’AZA-dC. 
B) Analysis by MIRA of the percentage of methylation enrichment of PTX3 regulatory regions in HcoEpiC cell line.  
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Results are expressed as percentage of enrichment relatively to input DNA normalized on a positive control and 
represented as mean ± SEM. *: p<0.05, **: p<0.01, ***: p<0.001, unpaired student's t test. 
 
Finally, to define the possible involvment of microRNA in PTX3 regulation in CRC, we used the 
bioinformatics browser mimiRNA (http://mimirna.centenary.org.au/mep/formulaire.html) to 
analyze the expressions of miRNA of our interest in healthy colon tissue and in colon malignant 
tumor. The analysis showed that there were not change in miRNA expression in healthy and 
colon tumor tissues (data not shown), indicating that miRNAs are not involved in the regulations 
of PTX3 in this tumor.   
                         
3.3 PTX3 regulatory regions became active in CRC cells upon co-treatment 
with 5’aza-dC and TNFα. 
 
Given that we observed a rescue of PTX3 expression upon treatment with 5’AZA-dC, we 
wondered whether it could be due to an effect on PTX3 regulatory regions. Thus, we performed 
a ChIP assay in the two CRC cell lines which were more responsive to treatment with the 
methylation inhibitor (RKO and HCT116, figures 27 and 28), in several stimulation conditions. 
PTX3 enhancers were inactive in CRC cells in basal conditions and upon treatment with 
inflammatory stimuli, whereas an increase in the levels of active markers and a reduction in  the 
levels of repression markers was observed upon treatment with 5’AZA-dC (figure 30 panel A 
and B). The most significant activation was achieved after co-stimulation with the methylation 
inhibitor and TNFα, in both cell lines. 
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Figure 30: PTX3 enhancer are inactive in CRC cell lines but become active after cotreatment with 5’AZA-dC 
and TNFα 
ChIP assay in the RKO cell line (A) and HCT116 cell line (B) in basal condition,  4h  after stimulation with TNFα, 
72h after treatment with 5’AZA-dC, and after cotreatment with 5’AZA-dC and TNFα, using antibodies recognizing 
H3K4me1, H3K27Ac and H3K27me3 histone modifications. Results are expressed as percentage of enrichment to 
IgG  and as a mean  ± SEM (N = 3 experiments) of values obtained according to the formula 100 × 2^ (input Ct − 
sample Ct) and then normalized on IgG.   *: p ≤ 0.05, **: p ≤ 0.01, ***: p ≤ 0.001; Student’s t-test. Each region 
analyzed with RT-qPCR is 150 bp long 
 
Then, to gain insight into the activity of PTX3 regulatory regions in colon cells and to confirm 
the data obtained in CRC cells, we performed a ChIP assay in human epithelial healthy colon 
cells (HCoEpiC), using Abs which characterize enhancer activity and also Abs specific for RNA 
Pol II and for SUZ12. We decided to focus on SUZ12 other than HEZ2 because of the higher 
affinity of the antibody observed in the previous experiments (figure 20). 
In basal conditions enhancers  were poised (figure 18)  because of the presence of H3K27me3 
and SUZ12, whereas, after treatment with TNFα, they became active, thus losing Polycomb and 
gaining the binding of H3K4me1, H3K27Ac and RNA Polymerase II. 
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Figure 31: PTX3 enhancers are poised in HCoEpiC cell lines and became active after treatment with TNFα. 
ChIP assay in the HCoEpiC cell line in basal condition and 4h  after stimulation with TNFα, using antibodies 
recognizing H3K4me1, H3K27Ac and H3K27me3 histone modifications and for SUZ12 and RNA Pol II. Results 
are expressed as percentage of enrichment to IgG  and as a mean  ± SEM (N = 3 experiments) of values obtained 
according to the formula 100 × 2^ (input Ct − sample Ct) and then normalized on IgG.   *: p ≤ 0.05, **: p ≤ 0.01, 
***: p ≤ 0.001; Student’s t-test. Each region analyzed with RT-qPCR is 150 bp long 
 
In line with these results, PTX3 promoter activity showed a similar response to the different 
stimuli in CRC cells:  we observed activation upon treatment with 5’AZA-dC and even a 
stronger activation in presence of inflammatory cytokines (Figure 32 panel A and B). 
 89 
In the PTX3 promoter of healthy colon cells the levels of H3K4me3, H3K9AC and RNA Pol II 
in basal conditions (Figure 32 panel C) significatively increased, after treatment with TNFα, thus  
favouring the binding of Pol II.  
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Figure 32: PTX3 promoter is no active in CRC cell lines until co-treatment with 5’AZA-dC and TNFα. 
A-B) ChIP assay in the RKO cell line (A) and HCT116 cell line (B) in basal condition,  4h  after stimulation with 
TNFα, 72h after treatment with 5’AZA-dC, and after cotreatment with 5’AZA-dC and TNFα, using antibodies 
recognizing H3K4me3, H3K27Ac, H3K9Ac and H3K27me3 histone modifications. 
C) ChIP assay in the HCoEpiC cell line in basal condition and  4h  after stimulation with TNFα, using antibodies 
recognizing H3K4me3, H3K27Ac, H3K9Ac and H3K27me3 histone modifications and for SUZ12 and RNA Pol II.  
Results are expressed as percentage of enrichment to IgG  and as a mean  ± SEM (N = 3 experiments) of values 
obtained according to the formula 100 × 2^ (input Ct − sample Ct) and then normalized on IgG.   *: p ≤ 0.05, **: p ≤ 
0.01, ***: p ≤ 0.001; Student’s t-test. Each region analyzed with RT-qPCR is 150 bp long 
 
Finally, we analyzed the binding of inflammatory transcription factors NF-kB and the AP-1 
subunits c-Fos and c-Jun regulate PTX3 expression. The data demonstrated that demethylation is 
was responsible for the binding of NF-kb and AP-1 to the PTX3 promoter in inflammatory 
conditions whereas the first enhancer only bound NF-kb, as we previously demonstrated in the 
8387 cell line (figure 19). 
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Figure adapted from Bonavita E, Gentile S., Rubino M,  et al. Accepted for publication in Cell 2015 
Figure 33: inflammatory transcription factors bind the PTX3 promoter and the first enhancer in CRC cell 
lines after co-treatment with 5’AZA.dC and TNFα. 
A-B) ChIP assay in the RKO cell line (A) and in HCT116 cell line (B) in basal condition and 4h after stimulation 
with TNFα, 72h after treatment with 5’AZA-dC, and after cotreatment with 5’AZA-dC and TNFα . We analyzed 
PTX3 enhancer 1 (panel 1), promoter regions (panel 2 and 3), and enhancer 2 at the end of the CpG island (panel 4) 
using antibodies anti-NF-kB (p65). Results are expressed as percentage of enrichment to IgG  and as a mean  ± SEM 
(N = 3 experiments) of values obtained according to the formula 100 × 2^ (input Ct − sample Ct) and then 
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normalized on IgG.   *: p ≤ 0.05, **: p ≤ 0.01, ***: p ≤ 0.001; Student’s t-test. Each region analyzed with RT-qPCR 
is 150 bp long.  
 
3.4 PTX3 is hypermetilated in several human tumors.  
 
In order to confirm in vivo the results obtained from CRC cell lines, we extended the 
methylation analysis to CRC samples derived from patients with colon cancer at different stages 
(stage 1 to 4), as well as in adenoma (Figure 34). For each tumor stage we analyzed also the 
corresponding healthy tissue. The data demonstrated that PTX3 regulatory regions were 
signifatively  methylated in all tumour stages compared to their healthy counterpart. Moreover, 
the methylation started to adenoma.      
 
Figure adapted from Bonavita E, Gentile S., Rubino M,  et al. Accepted for publication in Cell 2015 
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Figure 34: PTX3 regulatory regions are methylated in CRC patients compared with their healthy 
counterpart. 
Analysis by MIRA of the percentage of methylation enrichment of the promoter region and of the PTX3 CpG island 
in healthy colon epithelium, 5 high grade adenomas, 10 CRC and 2 healthy counterparts. 
Results are expressed as percentage of enrichment relatively to input DNA normalized on a positive control and 
represented as mean ± SEM. *: p<0.05, **: p<0.01, ***: p<0.001, unpaired student's t test. 
 
We further checked PTX3 methylation levels in  mesenchimal, including angiosarcoma, synovial 
sarcoma, leiomysarcoma, solitary fibrous tumour (SFT), chordoma, gastrointestinal stromal 
tumor (GIST), and desmoids tumors and in epithelial tumors, like squamous cell carcinoma 
(Figure 22). We also analyzed PTX3 methylation levels in both mesenchymal and epithelial 
healty tissue. As you can see in Figure 35, PTX3 regulatory regions were hypermetilated in 
different human tumors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure adapted from Bonavita E, Gentile S., Rubino M,  et al. Accepted for publication in Cell 2015 
* 
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Figure 35: PTX3  regulatory regions are methylated in several human tumors. 
Analysis by MIRA of the percentage of methylation enrichment of the promoter region and of the PTX3 CpG island 
in human mesenchymal and epithelial tumors: Skin healthy epithelial tissue from healthy counterparts of skin 
squamous carcinoma (n=5), healthy mesenchymal tissue from leiomyosarcoma (n=1), angiosarcoma (n=3), 
chordoma (n=3) and desmoid tumor (n=2) patients and 3-8 samples. 
Results are expressed as percentage of enrichment relatively to input DNA normalized on a positive control and 
represented as mean ± SEM. *: p<0.05, **: p<0.01, ***: p<0.001, unpaired student's t test. 
 
 
3.5 PTX3 methylation levels inversely correlate with PTX3 production in 
tumor samples.  
 
To further correlate PTX3 methylation in tumors with the lack of PTX3 expression in vivo, we 
performed immunohistochemistry assay in CRC samples and in their corresponding healthy 
counterpart. As shown in Figure 36, in healthy tissue in association with epithelial cells, we 
detected PTX3, which was hypomethylated in that tissue (figure 34). In contrast in CRC samples 
the protein was product by inflammatory cells and stroma cells but was not associated to 
epithelial tumor cells, which were found to be hypermetilated at levels of PTX3 enhancers and 
promoter.  
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Figure 36: PTX3 is express in healthy epithelial colon tissue but  it’s not  express in CRC cells.  
A-D) PTX 3 expression assessed by immunohistochemistry staining in colorectal cancer tumor 
tissues and adjacent nontumor tissues. 
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Discussion: 
- PTX3 expression is regulated by two enhancers during acute inflammation.   
 
In this study we investigated the mechanisms involved in the regulation of the expression of the 
long pentraxin PTX3 protein in physiological conditions, in inflammation and in cancer. We 
found that PTX3 trascription was regulated by 2 enhancers, highly conserved among species. 
The first one maps at 230 kb upstream of the TSS of the PTX3 promoter region and the second 
enhancer localized with the second exon of the gene.  
The long pentraxin PTX3 is highly regulates in different cell types, in particular in mononuclear 
phagocytes. PTX3 is poorly expressed in basal conditions, rapidly increases in the acute phase of 
inflammation responses and then its levels decrease, to basal levels in hours. PTX3 mRNA 
expression correlates with the activity of 2 different enhancers identified in this study. Indeed 
when PTX3 is highly express, after inflammatory stimulation, the enhancers are both active, 
whereas in basal condition they are poised and the promoter is the only active regulatory region.  
ChIP assay for transcription factors demonstrated that, after inflammatory stimuli acting through 
the TLR4 ad MyD88 pathways, both the first enhancer and the promoter binds the inflammatory 
transcription factor NF-kB, which regulate PTX3 gene expression. Given that differentiated cells 
have a unique repertoire of enhancers [187-191] characterized by specific transcription factors 
(TFs), we hypothesize that the first enhancer is activated and thus can regulate PTX3 expression, 
only during inflammatory conditions. In line with this hypothesizes, only in inflammatory 
conditions the first enhancer acquires the binding for RNA polymerase II. Thus we infer that this 
long-range enhancer might form a chromatin loop on the PTX3 promoter region, increasing its 
binding to Pol II and thus the gene expression.  
 97 
The second enhancer, as well as the PTX3 promoter, binds the RNA polymerase II both in basal 
condition and upon stimulation with TNFα, thus suggesting a functional role of the Pol II in the 
enhancer activity, or in the elongation of the PTX3 mRNA transcript. 
In basal conditions, PTX3 enhancers displayed both H3K27me3 repressor histone modifications 
and SUZ12 and EZH12 Polycomb Repressor Complex 2 (PRC2) subunit. This is in line with the 
results of different studies, which demonstrated that low-active genes can bind both RNA Pol II 
and PRC. PRC2 is a negative chromatin remodeler complex which is able to close the chromatin 
structure through H3K27me3, generated by EZH1/2 methyltransferasis. This complex can also 
reduce the activity of the RNA Pol II. [192,193]. Thus, we hypothesized that in basal condition, 
PRC2 could be responsible of silencing of PTX3 enhancers.  Upon stimulation with TNFα, the 
regulatory regions showed an increased Pol II activity, an enhanced gene expression and the lost 
of PCR2 subunits.  
Collectively, these data suggest that the high expression of PTX3 in inflammatory conditions 
depends on activation of enhancers, whereas the gene is  poorly active in basal condition through 
PRC2-dependant inactivation of the enhancers. 
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- miRNAs modulate PTX3 activity in inflammatory conditions through direct 
and indirect mechanisms.     
                     
MicroRNAs are regulators of numerous genes and pathways, can modulate the immune response, 
and play a crucial role in the regulation of inflammatory and autoimmune diseases and cancer. 
We confirmed with luciferase assays that PTX3 3‘UTR was targeted by 8 different microRNAs, 
as predicted by bioinformatics analysis. In particular, the most relevant seem to be mir-9 and 
miR-29 family, which reduced the luciferase activity by more than 40%, and the members of the 
miR-181 family which reduced luciferase activity by about 30%. 
We also tested the effect of these miRNAs on PTX3 expression at different time points after 
treatment with TNFα. MiR-181 family and in particular miR-29 family had a stronger effect on 
PTX3 protein expression at 24 hours, whereas miR-9 had a comparable effect at both time points.  
The analysis of PTX3 mRNA showed that some miRNAs could also reduce the messenger levels, 
maybe through the decay of the messenger or via indirect mechanisms, acting on the signalling 
pathways leading to PTX3 transcription.  
MiR-29 family reduced PTX3 messenger and protein production more than the other miRNAs. 
Among miR-181 family, only miR-181a and miR-181c had an effect on PTX3 mRNA, 
suggesting that each miRNA can target different genes, as reported in literature [194].  
The analysis of miRNA effects on PTX3 promoter through luciferase assay confirmed that both 
miR-29 and miR-181 families reduced the promoter activity, thus affecting the signalling 
pathway which induces PTX3 expression. In agreement, miR-181 family and miR-29b reduced 
the activity of NF-kB.   
 Collectively, these data indicate that the miRNA-dependent reduction of PTX3 mRNA is 
principally due to their role in the inhibition of transcription factors involved in PTX3 expression. 
Moreover, the study of the effects of inflammatory miRNA on PTX3 gene revealed that they 
regulated NF-kB, affecting both gene expression and production, in agreement with published 
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data [195]. This effect likely reflects at least in part the direct targeting by these miRNAs of 
molecules involved in signalling cascades culminating in the transcriptional activation of PTX3, 
including TRAF6 and IRAK1 for miR-146a [195] and MyD88 and TAB2 for miR-155 [196] 
In line with these hypotheses, protein interactions analysis, performed with IPA ingenuity 
software, revealed that PTX3 is part of a complex network: PTX3 can indirectly modulate the 
cytokines and the transcriptions factors that in turn regulate its expression and also modulate the 
activity of several miRNAs. This kind of feedback-regulation was previously proposed by Anya 
Rudnicki [197] and was then extended in our study. The complex and strong regulation of PTX3 
at different levels gives evidence of the great importance of this gene in the modulation of the 
inflammatory response, suggesting its potential role as hub gene. 
The RNA ImmunoPrecipitation (RIP) of the RISC in LPS stimulated macrophages allowed us to 
demonstrate the actual occurrence of aggregation of PTX3 mRNA and miRNAs acting directly 
on the PTX3 gene with the RISC. Indeed, PTX3 mRNA expression started reducing 6 hours 
upon treatment with LPS, the time necessary for its aggregation with the RISC. The microRNA 
of our interest were also highly associated with the complex at that time point: miR-29c and 
miR-181c in particular. Indeed, these two miRNAs, that were present at high levels in the RISC 
complex, bound also PTX3 3’UTR with a major efficiency compared to the other members of 
their family.  
Interestingly, the levels of all the miRNAs in the RISC decreased 8 hours after treatment with 
LPS, in line with PTX3 expression in the complex. Collectively, these data suggest that PTX3 is 
highly regulated by several miRNAs, including has-miR-224 detected by Anya Rudnicki and 
other ten miRNAs discovered in our study, that can act both in a direct or an indirect way, with a 
different specificity, mechanism and time of action. 
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-The methylation of the enhancers silence PTX3 gene in human cancer. 
 
In vivo studies in our laboratories demonstrated that PTX3-deficiency increases susceptibility to 
cancer development and growth in MCA-induced fibrosarcoma and DMBA-TPA induced skin 
cancer models. Thus, in these models PTX3 has a protective role against tumor. 
The analysis performed with Oncomine browser showed that PTX3 gene is expressed at low 
levels in several human cancer tissues compared to the healthy counterparts.  
Collectively, these data suggest that PTX3 might be involved in the pathogenesis of human 
cancers and the lack of his expression in several tumors could be due to alterations of regulatory 
mechanisms.  
In the last years, an increasing number of studies demonstrated that epigenetic mechanisms, 
together with genetic alterations, play a crucial role in the regulation of cancer development. 
Epigenetic alterations were proposed to be key regulators of the initiation of tumorigenesis [28, 
198]. In particular, the cancer epigenome is characterized by global DNA hypomethylation and 
site-specific hypermethylations that affect regulatory elements of oncosuppressor genes.   
Methylation assays on the PTX3 gene showed that CRC cells, which did not express PTX3, were 
hypermetylated, whereas healthy colon epithelial cells were hypomethylated and expressed 
PTX3.  We analyzed histone modifications that characterize gene regulatory elements, in CRC 
cells after several treatments and stimulations. The data obtained in 2 different lines indicated 
that the PTX3 promoter and the first enhancer became active only after 5’aza-dC and TNFα co-
treatment. Treatment with 5’aza-dC alone partially reverted PTX3 mRNA expression and protein 
production and induced only the activation of the PTX3 intragenic enhancer. This indicated that 
the second PTX3 enhancer, which in healthy cell lines bound RNA Pol II, both in basal and in 
inflammatory conditions, is sufficient to regulate PTX3 expression.  
Indeed, recent studies demonstrated that RNA Polymerase II activity started on  enhancers and 
after moved on target promoter.  Some groups suggested that the components of the transcription 
 101 
machinery and the preinitiation complex (PIC) were recruited to the enhancer. [199-201]. Only 
upon formation of the PIC on the enhancer, the complex can move along the promoter.  
Taken together, these data suggest that PTX3 intragenic enhancer is the key regulator of PTX3 
gene expression and it also controls the activity of both the promoter and long-range enhancer.  
Interestingly, both the promoter and the enhancers did not display H3K27me3 histone marker 
and Polycomb binding in CRC cells. Moreover, informatics analysis proved that the expression 
levels of PTX3 regulating miRNAs did not change between colon healthy and malignant cells. 
Thus, we suggest that DNA methylation is the only epigenetic mechanism regulating PTX3 gene 
expression in CRC, and this is dependent on silencing of enhancers. This is in line with recent 
results, demonstrating that the methylation of enhancers is responsible for silencing of target 
genes and it even plays a predominant role compared to promoter methylation [202,203].  
The PTX3 promoter and long-range enhancer were active in CRC cells only upon demethylation 
treatment and in the presence of an inflammatory stimulus, which leads to the binding of 
transcription factors on regulatory elements. This confirmed our previous suggestions about the 
role of NF-kB in the regulation of the activity of PTX3 first enhancer. Indeed, several works 
demonstrated that both enhancer activity and loop stabilization depend on the binding of specific 
transcription factors [204,205].  
The methylation analysis was then extended to CRC samples derived from patients with colon 
cancer at different stages (stage 1 to 4), as well as in adenoma. Both the enhancers were shown 
to be hypermethylated in tumors and the methylation started  at the adenoma stage, suggesting 
that this is an early event in the natural history of colorectal cancer [206]. In particular, PTX3 
intragenic enhancer was hypomethylated in the adenoma and hypermethylated in the advanced 
tumor stages, whereas the long-range enhancer was hypermethylated in adenoma stages and its 
methylation level decreased during tumor progression. 
Our in vivo experiments demonstrated that PTX3 is activated in order to reduce cancer related 
inflammatory response. Given that the activation of PTX3 first enhancer depends on 
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inflammatory stimuli, its high levels of methylation can be necessary to repress and avoid the 
PTX3 activation in response to the cancer related inflammation. Thus, we infer that PTX3 
methylation is not a casual event generated by the tumor mutagenesis, but it could be important 
events that favour the carcinogenesis itself [28, 198]. PTX3 enhancers were demonstrated to be 
hypermethylated in other tumours as well, both mesenchymal and epithelial, indicating that 
PTX3 silencing is a mechanism that might occur in several types of cancer. 
Given the importance of the connection between inflammation and cancer [207-208], we suggest 
that PTX3 may act as an extrinsic oncosupressor gene related to cancer inflammation in several 
tumors. 
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